Organigram (OGI) swings to profit as Q1 2026 revenue jumps and margins improve

Q: What margins and profitability metrics did Organigram (OGI) report for Q1 Fiscal 2026?

Gross margin before fair value adjustments was $23,517 , a 37% margin, and adjusted gross margin was $23,855 , or 38% . Adjusted EBITDA reached $5,265 , an 8% margin, while net income totaled $19,969 , reflecting both operational improvements and fair value gains.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

6-K

Rhea-AI Filing Summary

Organigram Global Inc. reported strong growth for the quarter ended December 31, 2025, with net revenue rising to $63,538 from $42,730 a year earlier, driven by higher Canadian recreational and international sales and contributions from the Motif acquisition.

Gross margin before fair value adjustments improved to $23,517, a 37% margin, while adjusted gross margin reached $23,855 or 38%. Adjusted EBITDA increased to $5,265 from $1,410, and net income swung to a profit of $19,969 versus a prior-year loss.

The company ended the quarter with $62,966 in cash, restricted cash and short‑term investments and working capital of $162,494, but used $18,117 of free cash flow. Management guides for Fiscal 2026 net revenue above $300 million, higher adjusted gross margins than Fiscal 2025, higher adjusted EBITDA, and positive free cash flow with capital expenditures under $10,000.

Organigram held the #1 share of the Canadian recreational cannabis market as of December 2025 and is expanding internationally, supported by a $124.6 million follow‑on investment from BAT and the Jupiter Pool. However, a material weakness in internal control over financial reporting remains under remediation, and pending U.S. legislative changes could force a sale, wind‑down or restructuring of hemp‑derived THC activities by November 2026.

Positive

Revenue and margin expansion: Net revenue rose to $63,538 (up 49% year over year), adjusted gross margin increased to 38%, and adjusted EBITDA grew to $5,265, indicating stronger scale and profitability in core operations.
Guidance for stronger Fiscal 2026: Management anticipates Fiscal 2026 net revenue above $300 million, adjusted gross margin exceeding Fiscal 2025 levels, higher adjusted EBITDA, and positive free cash flow with capital expenditures expected to be under $10,000.

Negative

Negative free cash flow and lower cash balance: Free cash outflow was $18,117 and total cash, restricted cash and short-term investments declined to $62,966, reflecting higher working capital needs and ongoing investment.
Internal control material weakness: Management concluded internal control over financial reporting was not effective as of December 31, 2025 due to remaining material weaknesses, with remediation still in progress throughout Fiscal 2026.
Regulatory risk to U.S. hemp business: A U.S. law amending the hemp definition could effectively eliminate hemp-derived THC products, potentially forcing sale, wind-down or restructuring of related U.S. activities by November 2026 if not changed.

Insights

Quarter shows strong growth and profitability, but cash burn, controls issues, and U.S. regulatory risks remain important constraints.

Organigram delivered a strong top-line and margin quarter. Net revenue grew to $63,538, up 49%, with recreational revenue at $54,071 and international and other at $9,467. Gross margin before fair value adjustments rose to 37%, and adjusted gross margin reached 38%, reflecting scale, mix, and cost efficiencies.

Profitability metrics improved sharply. Net income was $19,969, a significant reversal from the prior-year loss, largely aided by a $24,392 fair value gain on derivative liabilities, preferred shares and other financial assets. Adjusted EBITDA climbed to $5,265, an 8% margin, while non‑IFRS measures highlight underlying operational improvement despite lower international sales versus recent quarters.

Cash dynamics and risk factors temper the picture. The company used $16,013 in operating cash and posted free cash outflow of $18,117, while cash, restricted cash and short‑term investments declined to $62,966. Management still expects Fiscal 2026 net revenue to exceed $300 million, adjusted margins to surpass Fiscal 2025 levels, and positive free cash flow with capex under $10,000. Investors must weigh this outlook against ongoing material weaknesses in internal control over financial reporting, which management aims to remediate in Fiscal 2026, and U.S. legislative shifts that could require exiting or restructuring hemp‑derived THC activities by November 2026.

02/10/2026 - 07:41 AM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of February 2026

Commission File Number: 001-38885

ORGANIGRAM GLOBAL INC.

(Translation of registrant’s name into English)

145 King Street West, Suite 1400

Toronto, Ontario ,Canada M5H 1J8

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F [ ] Form 40-F [ X ]

SUBMITTED HEREWITH

Exhibits


99.1			Management's Discussion and Analysis for the three months ended December 31, 2025

99.2			Condensed Consolidated Interim Unaudited Financial Statements for the three months ended December 31, 2025

99.3			Form 52-109F2 - Certification of Interim Filings of Chief Executive Officer dated February 10, 2026

99.4			Form 52-109F2 - Certification of Interim Filings of Chief Financial Officer dated February 10, 2026

99.5			News Release announcing results for the three months ended December 31, 2025 dated February 10, 2026

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

ORGANIGRAM GLOBAL INC.

/s/ Greg Guyatt

Greg Guyatt

Chief Financial Officer

Date: February 10, 2026

INTRODUCTION

This Management’s Discussion and Analysis dated February 10, 2026 (this "MD&A") should be read in conjunction with the unaudited condensed consolidated interim financial statements (the “Interim Financial Statements”) of Organigram Global Inc. (together with its subsidiaries, the “Company”, "Organigram", "we", "us", or "our") for the three months ended December 31, 2025 (“Q1 Fiscal 2026”) and December 31, 2024 ("Q1 Fiscal 2025"), and the audited annual consolidated financial statements for the year ended September 30, 2025 ("Fiscal 2025") (the "Annual Financial Statements" and together with the Interim Financial Statements, the "Financial Statements"), including the accompanying notes thereto.

Financial data in this MD&A is based on the Financial Statements of the Company, and has been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board (“IASB”), unless otherwise stated. All financial information in this MD&A is expressed in thousands of Canadian dollars (“$”), except for share and per share calculations, references to $ millions and $ billions, per gram (“g”) or kilogram (“kg”) of dried flower and per milliliter (“mL”) or liter (“L”) of cannabis extracts calculations.

Refer to the cautionary statements regarding forward-looking information and non-IFRS measures found at the end of this MD&A.

BUSINESS OVERVIEW

NATURE OF THE COMPANY’S BUSINESS

Organigram is a licensed cannabis cultivator and producer of consumer packaged goods containing cannabis. The Company manufactures and distributes cannabis products to wholesale and retail channels in Canada, exports to international jurisdictions, and distributes hemp-derived tetrahydrocannabinol ("THC") beverages and edibles in the U.S.

Organigram operates five facilities across Canada:

Moncton Campus (Indoor Cultivation and Manufacturing)

The Moncton Campus is home to our 500,000+ square foot state-of-the-art flagship facility, which features three-tiered, strain-specific grow rooms with the ability to control critical environmental factors specific to the needs of each strain. The facility's capabilities include extraction, cannabinoid testing, and automated production and packaging lines. We have invested in cost-effective seed-based production, which contributes to efficiency through faster room turns, lower plant care, and higher yields. We are further enhancing these benefits through a proprietary genetic discovery that enables early identification of powdery mildew resistance in seedlings, contributing to the reduction of crop loss and production costs over time. Previously, confirming mildew resistance required approximately 90 days. With this discovery, screening can now occur within 10 days, enabling early removal of out-of-spec populations and reducing downstream crop loss and waste. This screening tool is proprietary and applicable across a wide range of genetics, unlike existing markers that are limited in scope.

Winnipeg Facility (Ingestible Products Manufacturing)

The Winnipeg Facility is a purpose-built, highly automated 51,000 square-foot ingestibles manufacturing facility capable of producing up to 48 million gummies annually. The Company's newly commissioned beverage manufacturing line is capable of producing up to 2.6 million beverage cans annually. The facility also contains specialized manufacturing equipment for the Company's FASTTM (Fast Acting Soluble Technology) nanoemulsion technology ("FASTTM") used in some of its ingestible products.

Lac-Supérieur Facility (Hash/Concentrates and Premium Flower)

The Lac-Supérieur Facility is a greenhouse facility which provides a strategic footprint in Quebec, spans 33,000 square feet of space, and is equipped to produce 2,400 kg of premium flower and over 2 million packaged units of hash annually.

Aylmer Facility (Extraction and Manufacturing)

The Aylmer Facility houses advanced extraction and manufacturing capabilities, including hydrocarbon and CO2 extraction refinement, formulation, post-processing of minor cannabinoids, and infused and regular pre-roll production.

London Facility (Warehousing and Distribution)

The London Facility is a centralized warehouse distribution hub in Ontario, Canada's most populous province. The facility supports growing demand for Organigram's products, optimizes fulfillment, and reduces the cost and complexity of shipping products from the Moncton Campus to Central and Western Canada.

As of the end of Q1 Fiscal 2026, Organigram held the #1 market share position in the Canadian recreational cannabis market1.

1 Multiple Sources (Hifyre, Weedcrawler, provincial boards, internal modelling) as of December, 2025.

MANAGEMENT’S DISCUSSION AND ANALYSIS | FOR THE THREE MONTHS ENDED DECEMBER 31, 2025 AND DECEMBER 31, 2024 1

STRATEGY

Our corporate strategy is to leverage our strengths in innovation, consumer focus, efficiency, and market expansion to profitably drive global growth and shareholder value.

1. Innovation

We are committed to maintaining a culture of innovation and have a track record of launching differentiated products that quickly capture market share.

Organigram maintains a Product Development Collaboration (“PDC”) with a wholly-owned subsidiary of British American Tobacco p.l.c. ("BAT"), its largest institutional shareholder and a leading multi-category consumer goods company, to develop next-generation cannabis products. Through the PDC we established a Centre of Excellence (“CoE”) at the Moncton Campus where we are licensed to conduct research on cannabis. Under the PDC Agreement dated 10 March 2021, Organigram is granted a worldwide, royalty‑free, non‑transferable license to any intellectual property developed by the PDC—sole in Canada and non‑exclusive internationally—on a perpetual basis. Both companies contribute scientists, researchers, and product developers to the CoE, which is jointly governed by a steering committee composed of equal representation from Organigram and BAT.

2. Consumer Focus

We maintain a diversified brand and product portfolio with competitive pricing that is aligned with evolving consumer preferences which we monitor through consumer and market research and social engagement.

3. Efficiency

We continue to reduce costs and improve scalability and margins through ongoing investments in facility automation, cultivation practices (including seed-based cultivation), and logistics efficiency, particularly at our London Facility.

4. Market Expansion

Organigram is committed to expanding its market presence through both organic growth and strategic diversification. Our key initiatives have included:

•Domestic expansion: acquisitions of cannabis cultivation and production facilities across Ontario, Québec, and Manitoba, enabling participation in all major Canadian product categories.

•International exports: shipments of bulk cannabis to Germany, Australia, and the United Kingdom (UK), strengthening Organigram’s position as a reliable global supplier.

•Strategic partnership with BAT: completion of a $124.6 million follow-on equity investment by BAT (the "Follow-on BAT Investment"), and creation of the Jupiter Pool to fund international growth opportunities, with initial investments in Steady State LLC (d/b/a Open Book Extracts ("OBX") (U.S.) and Sanity Group GmbH ("Sanity Group") (Germany).

•U.S. market entry: expansion into evolving hemp-derived THC beverages and edibles through the acquisition of Collective Project Limited ("CPL") and the launch of "happly", a lifestyle edibles brand focused on consumer mood states and functional ingredients2.

OUTLOOK

Market Size & Industry Trends

The Company maintains a positive outlook on the cannabis industry, both in Canada and internationally. Recreational cannabis sales in Canada are expected to total $6.4 billion in calendar 20283.

The Canadian market is stabilizing after years of oversupply and pricing pressure. Stabilization has been driven by consolidation, reduced capacity, and the absorption of supply by increased international demand. To address continued increases in international demand, several licensed producers ("LPs") have announced capacity expansion projects. Consumer preferences continue to evolve with sustained demand for high-THC, value-format flower, and rapid growth in the infused pre-roll category.

Regulatory scrutiny has intensified, particularly around inflated THC potency labeling, prompting initiatives by the Ontario Cannabis Store, Health Canada, and the Cannabis Standards Alliance of Canada to establish consistent testing and enforcement.

In November 2025, the U.S. enacted the Continuing Appropriations and Extensions Act of 2026 (H.R. 5371), which includes a provision (section 781) to amend the definition of hemp in the 2018 Farm Bill to effectively eliminate hemp-derived THC products, although the change does not become effective for 365 days from the date of enactment. Organigram’s U.S. offerings will be directly impacted by this change in law; additionally, Organigram has investments in hemp seed and hemp ingredient manufacturers in the U.S. that may be impacted by this legislation. Efforts are underway to repeal, replace, or delay this amendment, but whether any change will occur is uncertain. If current federal legislation is not amended or reversed, Organigram may have to sell, wind-down or otherwise restructure its hemp THC product related activities in the U.S. by November 2026.

2 See amendments to definition of hemp in the 2018 Farm Bill as described in greater detail in the "Outlook" section of this MD&A.

3 October, 2025 data from BDS Analytics, Inc. (BDSA).

MANAGEMENT’S DISCUSSION AND ANALYSIS | FOR THE THREE MONTHS ENDED DECEMBER 31, 2025 AND DECEMBER 31, 2024 2

LPs are increasingly seeking growth in international markets to increase their revenues and margins, and to solidify Canada's strong reputation abroad for producing high quality cannabis products.

Business Outlook

We expect to continue our revenue expansion through a combination of organic growth and M&A. Organic growth is anticipated to be supported by a strong innovation pipeline, improving cannabis quality, higher potency, and the commercialization of our FASTTM nanoemulsion technology in ingestible formats. M&A is expected to focus primarily on international opportunities that allow Organigram to build upon its growing international sales and support branded product sales in international markets. We also regularly evaluate opportunities in Canada that may strengthen our competitiveness.

In Fiscal 2025, Organigram achieved significantly higher international sales compared to the year ended September 30, 2024 ("Fiscal 2024"), as well as efficiencies in production, manufacturing, and logistics, driving adjusted gross margin4 growth, and adjusted gross margin4 of 38% in the fourth quarter of Fiscal 2025 ("Q4 Fiscal 2025"). In Q1 Fiscal 2026, we achieved an adjusted gross margin4 of 38% despite sequentially lower international sales. The sequential decline in international sales was primarily driven by higher-than-anticipated volumes of flower that did not meet international specifications. These volumes were redirected to the domestic market at the typical domestic margin profile. Assuming the Company continues to have a strong innovation pipeline, increasing international sales, high cannabis quality and higher potency, commercialization of FAST nanoemulsion technology in ingestible formats, and receipt of the EU-GMP certification of the Moncton Facility, the Company anticipates net revenue to exceed $300 million in the fiscal year ending September 30, 2026 ("Fiscal 2026"), and expects adjusted gross margin4 to exceed the level achieved in Fiscal 2025. The Company also anticipates adjusted EBITDA4 to surpass Fiscal 2025 levels and to generate positive free cash flow4 in Fiscal 2026, with capital expenditures expected to be less than $10 million.

Consistent with industry trends, our fourth fiscal quarter is typically one of the strongest of the year, reflecting heightened consumer activity and retailer replenishment ahead of the holiday period. This is usually followed by a seasonal slowdown in the first quarter before the market resumes its normal growth trajectory.

Our business outlook is subject to a number of assumptions and risk factors as further outlined in the "Cautionary Statement Regarding Forward-Looking Information" section of this MD&A.

International Market

The Company's international sales have increased since the first quarter of Fiscal 2024. As a result of initiatives aimed toward diversifying its international customer base, initiating branded sales outside of Canada, and establishing a foothold in the growing German cannabis market through a $21 million investment in Sanity Group, Organigram anticipates continued expansion of its international revenue, supported in part by the expected European Union Good Manufacturing Practice ("EU-GMP") certification of its Moncton Facility. The Company completed its EU-GMP audit in November 2024, and provided additional information to the regulator in October 2025. The Company is preparing follow-up responses and information for the regulator in response to feedback received in January 2026. Following provision of this information, the Company expects to await confirmation of certification or any required next steps.

Organigram serves a diverse international medical cannabis customer base in Australia, Germany, and the UK. The Company has also completed strategic investments in two U.S.-based companies, OBX and Phylos Bioscience Inc. ("Phylos"). Further, through its acquisition of CPL and launch of the happly brand, Organigram participates in the hemp-derived beverages and edibles segments in the U.S. and is continuing to monitor and prepare to respond to the regulatory developments in this space5.

We continue to monitor and evaluate opportunities in regulated recreational and medical markets outside of Canada, with a focus on the U.S., Europe, and Australia.

Future international shipments are subject to the timing and receipt of regulatory approval and an export permit from Health Canada, as well as timing and receipt of regulatory approval and an import permit from the purchasers' regulatory authority.

Jupiter Investment Pool

International expansion initiatives are expected to be supported by the $124.6 million Follow-on BAT Investment, with $83 million of the Follow-on BAT Investment earmarked for the Jupiter Pool. To date, approximately $23 million has been deployed from the Jupiter Pool to fund investments by Organigram in OBX and Sanity Group (see "Jupiter Strategic Investments" below). As of December 31, 2025, $59 million (being the remaining portion of the Jupiter Pool funds) is available to support continued expansion into the U.S. and other international markets in compliance with applicable laws.

4Adjusted gross margin, adjusted EBITDA and free cash flow are Non-IFRS Measures. See "Cautionary Statement Regarding Certain Non-IFRS Measures", "Financial Results and Review of Operations", and "Balance Sheet, Liquidity and Capital Resources" in this MD&A.

5See amendments to definition of hemp in the 2018 Farm Bill as described in greater detail in the "Outlook" section of this MD&A

MANAGEMENT’S DISCUSSION AND ANALYSIS | FOR THE THREE MONTHS ENDED DECEMBER 31, 2025 AND DECEMBER 31, 2024 3

As of December 31, 2025, the Company had access to $10 million of previously restricted funds pursuant to a temporary waiver granted by BAT. The waiver permits use of these funds for general purposes through November 8, 2026, after which the original restrictions are reinstated. The Company has classified these funds as unrestricted cash based on the terms and substance of the arrangement. As of December 31, 2025, the Company had drawn $2.4 million of these funds.

Jupiter Strategic Investments

On March 26, 2024, the Company completed its inaugural Jupiter Pool investment with a US $2 million investment into U.S.-based OBX.

On June 25, 2024, the Company completed its first European strategic investment, with an approximate $21 million investment into the German medical company, Sanity Group.

KEY DEVELOPMENTS DURING THE QUARTER AND SUBSEQUENT TO DECEMBER 31, 2025

In October 2025, Organigram launched happly, its third U.S. hemp-derived delta-9 brand, created specifically for the growing segment of consumers seeking ‘mindful recreation’ with THC products. The launch of happly follows the Company’s entry into the U.S. hemp-derived THC market with its lineup of Collective Project sparkling juices and Fetch sodas earlier this year6.

In November 2025, Organigram announced that James Yamanaka, formerly Global Head of Strategy for BAT, would be appointed as the Company’s new Chief Executive Officer. Mr. Yamanaka assumed the role effective January 15, 2026 and has also joined the Company's Board of Directors.

In December 2025, Organigram announced the expansion of its innovation investment in Phylos. Under the terms of the amended loan agreement with Phylos, Organigram will consolidate its existing investment with a new US $3 million advance, resulting in a combined total loan principal of US $10 million. The loan matures on May 25, 2028, and is subject to conditional conversion or other resolution mechanisms.

6 See amendments to definition of hemp in the 2018 Farm Bill as described in greater detail in the "Outlook" section of this MD&A.

MANAGEMENT’S DISCUSSION AND ANALYSIS | FOR THE THREE MONTHS ENDED DECEMBER 31, 2025 AND DECEMBER 31, 2024 4

FINANCIAL RESULTS AND REVIEW OF OPERATIONS

CAUTIONARY NOTE REGARDING NON-IFRS FINANCIAL MEASURES

The Company uses certain non-IFRS Measures such as adjusted EBITDA, adjusted gross margin and free cash flow in its MD&A and other public documents, which are not measures calculated in accordance with IFRS and have limitations as analytical tools. These performance measures have no prescribed meaning under IFRS, and therefore, amounts presented may not be comparable to similar data presented by other companies. The data is intended to provide additional information and should not be considered in isolation or as a substitute for measures of performance such as net income or other data prepared in accordance with IFRS. See the "Cautionary Statement Regarding Certain Non-IFRS Measures" section in this MD&A, and the following discussion.

FINANCIAL HIGHLIGHTS

Below is the period-over-period analysis of the changes that occurred between the three months ended December 31, 2025 and December 31, 2024. Commentary is provided in the pages that follow.

Net revenue is defined as gross revenue, net of customer fees, discounts, rebates, and sales returns and recoveries, less excise taxes. Revenue consists primarily of dried flower and cannabis derivative products sold to the recreational cannabis, medical cannabis, wholesale, and international cannabis markets.


	Q1-2026			Q1-2025			$ CHANGE		% CHANGE
Financial Results
Gross revenue	$	97,298		$	66,806		$	30,492	46	%
Net revenue	$	63,538		$	42,730		$	20,808	49	%
Cost of sales	$	40,021		$	28,615		$	11,406	40	%
Gross margin before fair value adjustments	$	23,517		$	14,115		$	9,402	67	%
Gross margin % before fair value adjustments	37		%	33		%			4	%
Realized fair value on inventories sold and other inventory charges	$	(16,911)		$	(13,066)		$	3,845	29	%
Unrealized gain on changes in fair value of biological assets	$	16,709		$	12,765		$	3,944	31	%
Gross margin	$	23,315		$	13,814		$	9,501	69	%
Operating expenses	$	26,733		$	20,615		$	6,118	30	%
Loss from operations	$	(3,418)		$	(6,801)		$	(3,383)	(50)	%
Other (income) expenses	$	(23,387)		$	16,156		$	(39,543)	nm

Net income (loss)	$	19,969		$	(22,957)		$	42,926	nm
Net earnings (loss) per common share, basic	$	0.148		$	(0.202)		$	0.350	nm
Net earnings (loss) per common share, diluted	$	0.146		$	(0.202)		$	0.348	nm

Net cash used in operating activities	$	(16,013)		$	(4,180)		$	11,833	283	%

Adjusted Gross Margin(1)	$	23,855		$	14,279		$	9,576	67	%
Adjusted Gross Margin %(1)	38		%	33		%			5	%
Adjusted EBITDA(1)	$	5,265		$	1,410		$	3,855	273	%

Financial Position
Working capital	$	162,494		$	162,532		$	(38)	—	%
Inventory and biological assets	$	132,711		$	103,953		$	28,758	28	%
Total assets	$	530,673		$	479,207		$	51,466	11	%
Non-current financial liabilities(2)	$	62,522		$	76,401		$	(13,879)	(18)	%

Note (1): Adjusted Gross Margin, Adjusted Gross Margin % and Adjusted EBITDA are Non-IFRS Measures. See "Cautionary Statement Regarding Certain Non-IFRS Measures" and the reconciliation to IFRS measures in the "Financial Results and Review of Operations" section of this MD&A.

Note (2): Non-current financial liabilities excludes non-monetary balances related to contingent share consideration, derivative liabilities and deferred income taxes.

NET REVENUE

For the three months ended December 31, 2025, the Company recorded net revenue of $63,538 compared to net revenue of $42,730 for the three months ended December 31, 2024. Net revenue increased on a period-over-period basis primarily due to an increase in international sales and recreational revenue, as well as the contributions from Motif Labs Limited's ("Motif") sales following the acquisition of Motif, for the period from December 6, 2024 to December 31, 2025.

MANAGEMENT’S DISCUSSION AND ANALYSIS | FOR THE THREE MONTHS ENDED DECEMBER 31, 2025 AND DECEMBER 31, 2024 5

REVENUE COMPOSITION

The Company’s net revenue composition by product category was as follows for the three months ended December 31, 2025 and December 31, 2024:


	Q1-2026	Q1-2025
Recreational, net of excise duty	54,071	38,558








International flower and beverages	5,042	3,330
Wholesale, medical and other	4,425	842
Total Net Revenue	$63,538	$42,730

COST OF SALES AND GROSS MARGIN

The gross margin for the three months ended December 31, 2025 was $23,315 compared to $13,814 for the three months ended December 31, 2024. The changes and significant items impacting the three months ended December 31, 2025 were: (i) higher recreational cannabis revenue; and (ii) higher unrealized gains on changes in the fair value of biological assets.

Included in gross margin are the changes in the fair value of biological assets related to IFRS standard IAS 41 – Agriculture. Unrealized gain on changes in the fair value of biological assets for the three months ended December 31, 2025 was $16,709 as compared to $12,765 for the three months ended December 31, 2024.

Cost of sales primarily consists of the following:

•Costs of sales of cannabis (dried flower, pre-rolls, and wholesale/international bulk flower), cannabis extracts, vapes, and other wholesale formats such as extract) include the direct costs of materials and packaging, labour, including any associated share-based compensation, and depreciation of manufacturing building and equipment. This includes cultivation costs (growing, harvesting, drying, and processing costs), extraction, vape filling, quality assurance and quality control, as well as packaging and labelling;

•Costs related to other products, such as vaporizers and other accessories;

•Shipping expenses to deliver product to the customer; and

•The production costs of late-stage biological assets that are disposed of, plants destroyed that do not meet the Company’s quality assurance standards, provisions for excess and unsaleable inventories, provisions related to adjustments to net realizable value that reduce the carrying value of inventory below the original production or purchase cost, and other production overhead.

ADJUSTED GROSS MARGIN

Adjusted gross margin is a on-IFRS Measure that the Company defines as net revenue less cost of sales, before the effects of: (i) unrealized gains on changes in fair value of biological assets; (ii) realized fair value on inventories sold and other inventory charges; (iii) provisions and impairment of inventories and biological assets; and (iv) provisions to net realizable value. The Company believes that this measure provides useful information to assess the profitability of the Company's operations as it represents the normalized gross margin generated from operations and excludes the effects of non-cash fair value adjustments on inventories and biological assets, which are required by IFRS. See "Cautionary Statement Regarding Certain Non-IFRS Measures". The most directly comparable measure to adjusted gross margin calculated in accordance with IFRS is gross margin before fair value adjustments.


	Q2-F24			Q3-F24			Q4-F24			Q1-F25			Q2-F25			Q3-F25			Q4-F25			Q1-F26
Net revenue	$	37,628		$	41,060		$	44,698		$	42,730		$	65,600		$	70,792		$	80,061		$	63,538
Cost of sales before adjustments	26,019			26,474			28,155			28,451			43,679			46,566			49,483			39,683
Adjusted Gross Margin (1)	11,609			14,586			16,543			14,279			21,921			24,226			30,578			23,855
Adjusted Gross Margin % (1)	31		%	36		%	37		%	33		%	33		%	34		%	38		%	38		%
Less:
Provisions and impairment of inventories and biological assets	314			628			2,043			13			548			921			1,603			65
Provisions to net realizable value	33			71			709			151			—			15			967			273
Realized fair value on inventories sold from acquisitions	—			—			—			—			1,586			867			—			—
Gross margin before fair value adjustments	$11,262			$13,887			$13,791			$	14,115		$	19,787		$	22,423		$	28,008		$	23,517
Gross margin % (before fair value adjustments)	30		%	34		%	31		%	33		%	30		%	32		%	35		%	37		%

MANAGEMENT’S DISCUSSION AND ANALYSIS | FOR THE THREE MONTHS ENDED DECEMBER 31, 2025 AND DECEMBER 31, 2024 6


Add: Realized fair value on inventories sold and other inventory charges	(11,062)			(13,728)			(15,365)			(13,066)			(14,192)			(14,461)			(25,406)			(16,911)
Unrealized gain on changes in fair value of biological assets	9,400			13,849			18,790			12,765			12,823			18,184			29,236			16,709
Gross margin(2)	$	9,600		$	14,008		$	17,216		$	13,814		$	18,418		$	26,146		$	31,838		$	23,315
Gross margin %(2)	26		%	34		%	39		%	32		%	28		%	37		%	40		%	37		%

Note 1: Adjusted Gross Margin and Adjusted Gross Margin % are non-IFRS measures. See "Cautionary Statement Regarding Certain Non-IFRS Measures" and "Financial Results and Review of Operations" in this MD&A

Note 2: Gross margin reflects the IFRS measure per the Company’s Financial Statements.

Both Adjusted Gross Margin and gross margin before fair value adjustments improved throughout Fiscal 2024. This improvement is attributed to several factors, including lower cultivation and post-harvest costs, reduced inventory provisions, lower depreciation resulting from impairment charges recorded in fiscal year 2023 and higher recreational cannabis revenue. In the first quarter of Fiscal 2025, gross margin declined primarily due to lower unrealized gain on changes in fair value of biological assets and lower international sales. In the second quarter of Fiscal 2025, gross margin declined primarily due to the fair value adjustment on inventories acquired through the Motif acquisition and subsequently sold, as required under IFRS. In the third and fourth quarter of Fiscal 2025, the gross margin increase was driven by a higher proportion of international sales with stronger margins, lower cost of sales per unit achieved through greater scale and operating efficiencies (including but not limited to an improvement in yields), and higher unrealized gain on changes in fair value of biological assets, partially offset by lower margins on domestic white label and B2B sales. In Q1 Fiscal 2026, the gross margin declined primarily due to lower unrealized gain on changes in fair value of biological assets.

OPERATING EXPENSES


	Q1-2026		Q1-2025		CHANGE		% CHANGE

General and administrative	$	14,950	$	11,233	$	3,717	33	%
Sales and marketing	8,991		5,804		3,187		55	%
Research and development	2,084		2,369		(285)		(12)	%
Share-based compensation	708		1,209		(501)		(41)	%


Total operating expenses	$	26,733	$	20,615	$	6,118	30	%

GENERAL AND ADMINISTRATIVE

For the three months ended December 31, 2025, the Company incurred general and administrative expenses of $14,950 compared to $11,233 for the three months ended December 31, 2024. The increased expenses mainly relate to higher depreciation and amortization resulting from the acquisitions of Motif and CPL, as well as increased professional fees. These expenses as a percentage of net revenue decreased to 24% from 26% in the comparative period.

SALES AND MARKETING

For the three months ended December 31, 2025, the Company incurred sales and marketing expenses of $8,991 or 14% of net revenues as compared to $5,804 or 14% of net revenues for the three months ended December 31, 2024. These expenses as % of net revenue remained flat year over year.

RESEARCH AND DEVELOPMENT

Research and development costs of $2,084 decreased from $2,369 in the comparative period. The decrease was primarily driven by lower investment in foundational research within the PDC, reflecting a shift toward more targeted, strategic product development, as well as headcount reductions resulting from synergies realized through the Motif acquisition.

SHARE-BASED COMPENSATION

For the three months ended December 31, 2025, the Company recognized $708 of share-based compensation expense, compared to $1,209 for the three months ended December 31, 2024. The decrease in expense during the current period is primarily due to cancellation of certain performance share units ("PSUs"), resulting in a reduction in recognized share‑based compensation.

Share-based compensation represents a non-cash expense and was valued using the Black-Scholes valuation model for stock options and using the fair value of the shares on the date of the grant for restricted share units ("RSUs"). The fair value of performance share units ("PSUs") was based on the Company’s share price at the grant date, adjusted for an estimate of likelihood of achievement of the defined performance criteria.

MANAGEMENT’S DISCUSSION AND ANALYSIS | FOR THE THREE MONTHS ENDED DECEMBER 31, 2025 AND DECEMBER 31, 2024 7

OTHER (INCOME) EXPENSES


	Q1-2026		Q1-2025		CHANGE		% CHANGE

Investment income, net of financing costs	$(93)		$(825)		$(732)		(89)	%
Acquisition and transaction costs	1,606		4,504		(2,898)		(64)	%





Change in fair value of contingent consideration	(1,809)		—		(1,809)		(100)	%

Change in fair value of derivative liabilities, preferred shares and other financial assets	(24,392)		14,495		(38,887)		nm

Other non-operating expenses	1,301		(2,018)		3,319		nm
Total other (income)/expenses	$	(23,387)	$	16,156	$	(39,543)	nm

INVESTMENT INCOME, NET OF FINANCING COSTS

Investment income (net of financing costs) of $93 was earned during the three months ended December 31, 2025, compared to $825 during the three months ended December 31, 2024. The change in investment income was primarily as a result of lower daily cash balance in the current period as compared to the three months ended December 31, 2024.

ACQUISITION AND TRANSACTION COSTS

Acquisition and transaction costs decreased to $1,606 for the three months ended December 31, 2025, from $4,504 for the three months ended December 31, 2024. The decrease was primarily attributable to lower transaction related activity in the current period. Costs incurred during the three months ended December 31, 2025 mainly related to severance payments made to employees as part of restructuring initiatives. In contrast, costs incurred in the comparative period were primarily related to due diligence, regulatory filings, legal and advisory services, and integration related expenses associated with the acquisition of Motif.

CHANGE IN FAIR VALUE OF CONTINGENT CONSIDERATION

Change in fair value of contingent consideration was a gain of $1,809 for the three months ended December 31, 2025, compared to a gain of $nil for the three months ended December 31, 2024.The gain in the current period was due to the revaluation of the contingent liability payable to the former vendors of Motif.

CHANGE IN FAIR VALUE OF DERIVATIVE LIABILITIES, PREFERRED SHARES AND OTHER FINANCIAL ASSETS

Change in fair value of derivative liabilities, preferred shares and other financial assets was a gain of $24,392 for the three months ended December 31, 2025, compared to a loss of $14,495 for the three months ended December 31, 2024. The following are the fair value changes that were recognized for the nine months ended December 31, 2025, and 2024:


	THREE MONTHS ENDED
	DECEMBER 31, 2025		DECEMBER 31, 2024
Investment in Phylos	$	2,888	$	(2,471)
Investment in OBX	(67)		(288)
Investment in Sanity Group (convertible loan)	(700)		(1,151)
Investment in Sanity Group (common shares)	113		47
Top-up Rights	(12,157)		18,945
Commitment to fund third tranche of Phylos convertible loan	30		(303)
Commitment to issue Preferred Shares	—		(671)
Warrants	(862)		(3,348)
Preferred shares	(13,637)		3,735
	$	(24,392)	$	14,495

NET INCOME

Net income for the three months ended December 31, 2025 was $19,969 or $0.148 and $0.146 per Common Share (basic and diluted, respectively), compared to net loss of $27,461 or $0.202 per Common Share (basic and diluted) for the three months ended December 31, 2024. The increase in net income from the comparative period is primarily attributable to (i) higher gross margins; and (ii) higher fair value gain recognized in relation to the top-up-rights of BAT (the "Top-up Rights"), preferred shares, share warrants and other financial assets.

MANAGEMENT’S DISCUSSION AND ANALYSIS | FOR THE THREE MONTHS ENDED DECEMBER 31, 2025 AND DECEMBER 31, 2024 8

SUMMARY OF QUARTERLY RESULTS


	Q2-F24		Q3-F24		Q4-F24		Q1-F25		Q2-F25		Q3-F25		Q4-F25		Q1-F26
Financial Results
Adult-use recreational cannabis revenue (net of excise duty)	$	33,118	$	36,467	$	38,839	$	38,558	$	56,658	$	59,918	$	66,415	$	54,071



Medical international, wholesale and other revenue	$	4,510	$	4,593	$	5,859	$	4,172	$	8,942	$	10,874	$	13,646	$	9,467
Net revenue	$	37,628	$	41,060	$	44,698	$	42,730	$	65,600	$	70,792	$	80,061	$	63,538
Net income (loss)	$	(27,075)	$	2,818	$	(5,433)	$	(22,957)	$	42,456	$	(6,294)	$	(37,964)	$	19,969
Net earning (loss) per common share, basic	$	(0.297)	$	0.027	$	(0.050)	$	(0.202)	$	0.329	$	(0.047)	$	(0.283)	$	0.148
Net earning (loss) per common share, diluted	$	(0.297)	$	0.026	$	(0.050)	$	(0.202)	$	0.318	$	(0.047)	$	(0.283)	$	0.146
Operational Results



Employee headcount (#)	987		914		875		1,241		1,150		1,178		1,139		1,137

In Fiscal 2024, net revenue had sequentially increased as a result of higher international sales. In Q1 Fiscal 2025, net revenue marginally decreased primarily as a result of lower international sales. In the second quarter of Fiscal 2025, the Company's international sales increased. Additionally, recreational net revenue also increased during this period. In the third quarter of Fiscal 2025, the Company achieved record net revenue and sequentially higher international sales. In the fourth quarter of Fiscal 2025, net revenue was the highest that the Company has reported in the preceding eight quarters. In Q1 Fiscal 2026, net revenue decreased due to lower recreational and international sales.

In the second quarter of Fiscal 2024, the Company recorded a higher net loss primarily due to lower gross margin, higher operating expenses and lower gain on the change in fair value of derivative liabilities. In the third quarter of Fiscal 2024, both net revenue and gross margin increased, resulting in net income. In the fourth quarter of Fiscal 2024, the Company recorded a net loss primarily due to an impairment loss of $4,773 for investments in associates and change in fair value of derivative liabilities and other financial assets (investments which are measured at fair value through profit and loss) of $1,642. In Q1 Fiscal 2025, the Company's net loss increased, primarily due to increases in fair value losses on derivative liabilities and higher acquisition and transaction costs related to the acquisition of Motif. In the second quarter of Fiscal 2025, the Company recorded net income of $42,456. This increase compared to the prior quarter is primarily due to higher gross margins and higher gains from changes in the fair value of derivative liabilities, preferred shares, contingent consideration, and other financial assets. In the third quarter of Fiscal 2025, the Company recorded net loss of $6,294 primarily due to an increase in fair value losses on derivative liabilities and preferred shares. In the fourth quarter of Fiscal 2025, the Company's net loss increased, primarily due to increases in fair value losses on derivative liabilities and preferred shares. In Q1 Fiscal 2026, the Company reported net income of $19,969. The increase in net income was primarily due to higher gains from changes in the fair value of derivative liabilities and preferred shares.

MANAGEMENT’S DISCUSSION AND ANALYSIS | FOR THE THREE MONTHS ENDED DECEMBER 31, 2025 AND DECEMBER 31, 2024 9

Adjusted EBITDA

Adjusted EBITDA is a non-IFRS measure and the Company calculates adjusted EBITDA as net income (loss) excluding: investment income, net of financing costs; income tax expense (recovery); depreciation, amortization, impairment, normalization of depreciation add-back due to changes in depreciable assets resulting from impairment charges, (gain) loss on disposal of property, plant and equipment (per the consolidated statement of cash flows); share-based compensation (per the consolidated statement of cash flows); share of loss (gain) from investments in associates including impairment loss; change in fair value of contingent consideration; change in fair value of derivative liabilities, preferred shares and other financial assets; expenditures incurred in connection with R&D activities (net of depreciation); unrealized (gain) loss on changes in fair value of biological assets; realized fair value on inventories sold and other inventory charges; provisions and net realizable value adjustments related to inventory and biological assets; government subsidies, insurance recoveries and other non-operating expenses (income); legal provisions (recoveries); incremental fair value component of inventories sold from acquisitions; ERP implementation costs; transaction costs; share issuance costs; and provision for expected credit losses. Management believes that adjusted EBITDA is intended to provide a proxy for the Company’s operating cash flow and derives expectations of future financial performance for the Company, and excludes adjustments that are not reflective of current operating results. See "Cautionary Statement Regarding Certain Non-IFRS Measures". The most directly comparable measure to adjusted EBITDA calculated in accordance with IFRS is net income (loss).

During the second quarter of Fiscal 2024, management changed the calculation of adjusted EBITDA to include provisions for expected credit losses and has conformed prior quarters accordingly.


Adjusted EBITDA (Non-IFRS Measure)
Adjusted EBITDA Reconciliation	Q2-F24			Q3-F24			Q4-F24			Q1-F25			Q2-F25			Q3-F25			Q4-F25			Q1-F26
Net income (loss) as reported	$	(27,075)		$	2,818		$	(5,433)		$	(22,957)		$	42,456		$	(6,294)		$	(37,964)		$	19,969
Add/(deduct):
Investment income, net of financing costs	(650)			(1,179)			(960)			(825)			(179)			(73)			(73)			(93)
Income tax (recovery) expense	(30)			—			30			—			(106)			(9,903)			(3,761)			—
Depreciation and amortization	3,130			3,039			3,073			3,387			4,839			4,789			4,960			4,980


ERP implementation costs	173			7			465			744			628			1,217			951			407
Acquisition and transaction costs	(170)			421			74			4,504			974			654			448			1,606
Inventory and biological assets fair value and NRV adjustments	2,009			578			(673)			465			1,917			(2,787)			(1,260)			540
Incremental fair value component on inventories sold from acquisitions	—			—			—			—			1,586			897			—			—
Share-based compensation	1,995			2,087			1,093			1,325			938			1,007			947			770
Other (income) expenses(1)	12,778			(6,687)			6,646			12,477			(50,728)			13,511			42,539			(24,900)
Provision for non-recurring credit losses	4,239			—			—			—			—			—			—			—
Research and development expenditures, net of depreciation	2,556			2,381			1,545			2,290			2,583			2,676			3,056			1,986
Adjusted EBITDA	$	(1,045)		$	3,465		$	5,860		$	1,410		$	4,908		$	5,694		$	9,843		$	5,265

Divided by: net revenue	37,628			41,060			44,698			42,730			65,600			70,792			80,061			63,538

Adjusted EBITDA Margin % (Non-IFRS Measure)	(3)		%	8		%	13		%	3		%	7		%	8		%	12		%	8		%

Note 1: Other (income) expenses(1) includes share of loss from investments in associates, (gain) loss on disposal of property, plant and equipment, change in fair value of derivative liabilities, preferred shares, contingent consideration and other financial assets, and certain other non-operating (income) expenses.

In the second quarter of Fiscal 2024, the Company's Adjusted EBITDA position was a loss of $1,045. In the third quarter of Fiscal 2024, as a result of higher recreational cannabis revenue and a higher adjusted gross margin resulting from lower cultivation and post-harvest costs, adjusted EBITDA increased to $3,465. In the fourth quarter of Fiscal 2024, the Company achieved adjusted EBITDA of $5,860. During Q1 Fiscal 2025, the adjusted EBITDA decreased to $1,410 due to lower international sales. In the second quarter of Fiscal 2025, the Company's international sales increased and the adjusted EBITDA increased to $4,908. During third quarter of Fiscal 2025, the Company's recreational and international sales increased, resulting in an increase in adjusted EBITDA to $5,694. In fourth quarter of Fiscal 2025, continued growth in net revenues and lower costs of production (on a per unit basis), resulted in adjusted EBITDA of $9,843. During Q1 Fiscal 2026, adjusted EBITDA decreased to $5,265 due to lower international and recreational sales, partially offset by the realization of cost savings initiatives.

MANAGEMENT’S DISCUSSION AND ANALYSIS | FOR THE THREE MONTHS ENDED DECEMBER 31, 2025 AND DECEMBER 31, 2024 10

BALANCE SHEET, LIQUIDITY AND CAPITAL RESOURCES

The following represents selected balance sheet highlights of the Company as at December 31, 2025 and September 30, 2025:


	DECEMBER 31, 2025		SEPTEMBER 30, 2025		% CHANGE
Cash, restricted cash and short-term investments	$	62,966	$	84,420	(25)	%
Inventories	$	116,221	$	106,023	10	%
Working capital	$	162,494	$	158,738	2	%
Total assets	$	530,673	$	562,211	(6)	%

Non-current financial liabilities(1)	$	62,522	$	76,401	(18)	%
Total shareholders' equity	$	369,456	$	349,130	6	%

Note 1: Non-current financial liabilities excludes non-monetary balances related to contingent share consideration, derivative liabilities and deferred income taxes.

On December 31, 2025, the Company had total cash (including restricted cash and short-term investments) of $62,966 compared to $84,420 at September 30, 2025. The decrease is primarily due to an increase in working capital of $3,756, purchase of property, plant and equipment of $2,104 and an additional investment of $2,510 in Phylos during the current period.

Management believes its capital position provides sufficient liquidity to fund operations over the medium term. The Company's cash balances fluctuate significantly on a quarterly basis due to the timing of excise duty remittances. Management continues to assess additional financing alternatives, including to support strategic growth initiatives. Subject to prevailing market conditions, the Company may access additional equity or debt financing through the capital markets if required. The Common Shares are listed for trading on both the NASDAQ and TSX, and there is analyst coverage among sell-side brokerages. However, there can be no assurance that capital will be available on terms acceptable to the Company or at all.

The following highlights the Company’s cash flows during the three months ended December 31, 2025 and December 31, 2024:


	THREE MONTHS ENDED
		DECEMBER 31, 2025		DECEMBER 31, 2024
Cash used in:
Operating activities		$	(16,013)	$	(4,180)
Financing activities		(450)		(202)
Investing activities		(4,344)		(61,553)
		$	(20,807)	$	(65,935)
Effect of foreign exchange on cash		$	(626)	2,014
Net cash used		$	(21,433)	$	(63,921)
Cash position
Beginning of period		83,594		132,605
End of period		$	62,161	$	68,684
Short-term investments		805		2,499
Cash (including restricted cash) and short-term investments		$62,966		$71,183

Cash used in operating activities after working capital changes for the three months ended December 31, 2025 was $16,013, compared to cash used of $4,180 for the three months ended December 31, 2024. The increase in cash used by operating activities is primarily due to an increase in working capital during the current period.

Cash used in financing activities for the three months ended December 31, 2025 was $450. In comparison, for the three months ended December 31, 2024, cash used in financing activities was $202. The increase in cash used in financing activities in the current period was primarily due to higher interest expense on right-of-use assets that were acquired on account of acquisition of Motif leases.

Cash used in investing activities for the three months ended December 31, 2025 was $4,344, compared to cash used in investing activities of $61,553 for the three months ended December 31, 2024. The decrease in cash used in investing activities is primarily due to the acquisition of Motif, which was completed in the comparative period.

MANAGEMENT’S DISCUSSION AND ANALYSIS | FOR THE THREE MONTHS ENDED DECEMBER 31, 2025 AND DECEMBER 31, 2024 11

Free Cash Flow

Free cash flow is a non-IFRS measure and is calculated by the Company as net cash provided by or used in operating activities less the purchase of property, plant and equipment. Management believes that free cash flow is a useful indicator of the Company's capacity to fund operations from internally generated cash flows, without the need for additional borrowings or use of existing cash reserves under normal operating conditions. See "Cautionary Statement Regarding Certain Non-IFRS Measures". The most directly comparable measure to free cash flow in accordance with IFRS is net cash and restricted cash provided by (used in) operating activities.


	THREE MONTHS ENDED
	DECEMBER 31, 2025		DECEMBER 31, 2024
Net cash and restricted cash used in operating activities	$	(16,013)	$	(4,180)
Deduct:
Purchase of property, plant and equipment	(2,104)		(1,626)
Free cash flow	$	(18,117)	$	(5,806)

Free cash flow for the three months ended December 31, 2025 was $18,117. In comparison, for the three months ended December 31, 2024, free cash used flow was $5,806. The decrease in free cash flow is primarily due to the increase in the Company's working capital.

OFF BALANCE SHEET ARRANGEMENTS

There were no off-balance sheet arrangements during the three months ended December 31, 2025.

RELATED PARTY TRANSACTIONS

MANAGEMENT AND BOARD COMPENSATION

Key management personnel are those persons having the authority and responsibility for planning, directing, and controlling activities of the Company, directly or indirectly. The key management personnel of the Company are the members of the Company’s executive management team and Board of Directors. The transactions are conducted at arm's length and in the normal course of operations.

For the three months ended December 31, 2025 and December 31, 2024, the Company’s expenses included the following management and Board of Directors compensation:


	THREE MONTHS ENDED
		DECEMBER 31, 2025		DECEMBER 31, 2024
Salaries and bonus		$	1,377	$	1,302
Share-based compensation		476		775
Total key management compensation		$	1,853	$	2,077

During the three months ended December 31, 2025, 650,061 RSUs (December 31, 2024 – 404,905), were granted to key management personnel with an aggregate fair value of $1,586 (December 31, 2024 – $2,724). In addition, for the three months ended December 31, 2025, 379,254 PSUs (December 31, 2024 – 404,905) were issued to key management personnel with an aggregate fair value of $925 (December 31, 2024 – $1,843).

SIGNIFICANT TRANSACTIONS WITH ASSOCIATES AND JOINT OPERATIONS

The Company has transactions with related parties, as defined in IAS 24 - Related Party Disclosures, all of which are undertaken in the normal course of business.

For the three months ended December 31, 2025, under the product development collaboration agreement between the Company and BAT dated March 10, 2021, BAT incurred $675 (December 31, 2024 – $418) of direct expenses and the Company incurred $1,227 (December 31, 2024 – $1,474) of direct expenses and capital expenditures of $0 (December 31, 2024 – $nil) related to the Centre of Excellence. The Company recorded in the three months ended December 31, 2025, $951 (December 31, 2024 – $946) of these expenditures within research and development expense in the condensed consolidated interim statement of operations and comprehensive income (loss). For the three months ended December 31, 2025, the Company recorded $nil (December 31, 2024 – $nil) of capital expenditures which are included in the condensed consolidated interim statement of financial position.

MANAGEMENT’S DISCUSSION AND ANALYSIS | FOR THE THREE MONTHS ENDED DECEMBER 31, 2025 AND DECEMBER 31, 2024 12

At December 31, 2025, there is a balance receivable from BAT of $848 (September 30, 2025 – $701).

FAIR VALUE MEASUREMENTS

(i) Financial Instruments

Financial instruments recorded at fair value on the consolidated statement of financial position are classified using a fair value hierarchy that reflects the significance of the inputs used in making the measurements. The Company categorizes its fair value measurements according to a three-level hierarchy. The hierarchy prioritizes the inputs used by the Company’s valuation techniques. A level is assigned to each fair value measurement based on the lowest-level input significant to the fair value measurement in its entirety.

The three levels of the fair value hierarchy are described as follows:

•level 1 inputs are quoted prices in active markets for identical assets or liabilities that the entity can access at the measurement date;

•level 2 inputs, other than quoted prices included within level 1, that are observable for the asset or liability, either directly or indirectly; and

•level 3 inputs are unobservable inputs for the asset or liability.

As at December 31, 2025, the Company held financial instruments that are measured at fair value at each reporting date. The valuation of these instruments is performed using various models, which, due to the complexity and nature of the instruments, primarily rely on Level 3 inputs within the fair value hierarchy. These inputs are unobservable and reflect the Company’s own assumptions about the assumptions that market participants would use in pricing the instruments. Refer to Note 16 of the Interim Financial Statements for further information.

(ii) Biological Assets

Biological assets, consisting of cannabis plants, are measured at fair value less costs to sell in accordance with the IFRS as issued by the IASB. The fair value measurement is categorized within Level 3 of the fair value hierarchy due to the use of significant unobservable inputs. These inputs include expected yield per plant, average selling price (net of post-harvest costs), wastage rates, post-harvest processing costs, and the stage of growth of the plants at the reporting date. Changes in these assumptions could result in significant variations in the fair value of biological assets. Refer to Note 6 of the Interim Financial Statements for further information.

OUTSTANDING SHARE DATA

(i) Outstanding Shares, Warrants and Options and Other Securities

The following table sets out the number of Common Shares, preferred shares, options, warrants, Top-up Rights, RSUs and PSUs outstanding of the Company as at December 31, 2025 and February 5, 2026.


	DECEMBER 31, 2025	FEBRUARY 5, 2026
Common shares issued and outstanding	135,132,782	$	135,135,993
Preferred shares(1)	13,794,163	$	13,794,163
Options	2,231,345	$	2,222,008
Warrants	4,450,500	$	4,450,500
Top-up Rights	18,964,209	$	18,872,854
Restricted share units	3,485,759	$	3,402,830
Performance share units	2,192,944	2,034,095
Total fully diluted shares	180,251,702	$	179,912,443

Note 1: The preferred shares are eligible, under certain scenarios, to be converted into common shares equaling 14,994,047 consisting of the original preferred shares of 13,794,163 that convert into one common share and accretion amounts that accrue to the preferred shares at an annual rate of 7.5% per annum. Since the preferred shares were issued under the second and third tranches of the Follow-On BAT Investment, they have collectively accrued 1,199,884 of additional common share conversion value.

CRITICAL ACCOUNTING ESTIMATES AND JUDGMENTS

The preparation of the Financial Statements under IFRS requires management to make judgments, estimates, and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. The estimates and

MANAGEMENT’S DISCUSSION AND ANALYSIS | FOR THE THREE MONTHS ENDED DECEMBER 31, 2025 AND DECEMBER 31, 2024 13

associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised, if the revision affects only that period, or in the period of the revision and future periods, if the revision affects both current and future periods.

There have been no changes in the Company's critical accounting estimates during the three months ended December 31, 2025. For additional information on the Company’s accounting policies and key estimates, refer to the note disclosures in the Annual Financial Statements and MD&A as at and for the year ended September 30, 2025.

Adoption of New Accounting Pronouncements

Amendment to IAS 21: Lack of Exchangeability
In August 2023, the IASB amended IAS 21 to clarify when a currency is exchangeable into another currency and how a company estimates a spot rate when a currency lacks exchangeability. The amendments are effective for annual reporting periods beginning on or after January 1, 2025. The Company’s international transactions are limited to a few countries, such as the United States, the United Kingdom, Australia and Germany. These countries all have active markets for their currencies and therefore, there is no risk of a lack of exchangeability for these currencies.

These amendments do not have any material impact on the Company’s consolidated financial statements.

CONTINGENT LIABILITIES

The Company recognizes loss contingency provisions for probable losses when management can reasonably estimate the loss. When the estimated loss lies within a range, the Company records a loss contingency provision based on its best estimate of the probable loss. If no particular amount within that range is a better estimate than any other amount, the mid-point of the range is used. As information becomes known a loss contingency provision is recorded when a reasonable estimate can be made. The estimates are reviewed at each reporting date and the estimates are changed when expectations are revised. An outcome that deviates from the Company’s estimate may result in an additional expense or release in a future accounting period.

DISCLOSURE CONTROLS AND PROCEDURES AND INTERNAL CONTROL OVER FINANCIAL REPORTING

In accordance with National Instrument 52-109 - Certification of Disclosure in Issuers’ Annual and Interim Filings (“NI 52-109”) and Rule 13a-15 under the United States Securities Exchange Act of 1934, as amended (the “Exchange Act”), the establishment and maintenance of Disclosure Controls and Procedures (“DCP”) and Internal Control Over Financial Reporting (“ICFR”) is the responsibility of management.

The Company engaged PKF O'Connor Davies ("PKF"), the Company's independent registered public accounting firm, to perform an “integrated audit”, which encompassed an opinion on the fairness of presentation of the Company’s annual consolidated financial statements for the year ended September 30, 2025, as well as an opinion on the effectiveness of the Company’s ICFR. PKF, has audited the Company's Annual Financial Statements and has issued an adverse report on the effectiveness of ICFR. PKF‘s audit report on the Company’s ICFR is incorporated by reference into the Company’s annual report on Form 40-F under the Exchange Act for the year ended September 30, 2025.

DISCLOSURE CONTROLS AND PROCEDURES

The Company maintains a set of DCP designed to provide reasonable assurance that information required to be publicly disclosed is recorded, processed, summarized and reported on a timely basis. As required by NI 52-109 and Exchange Act Rule 13a-15(b), an evaluation of the design and operation of our DCP was completed prior to the date of this MD&A under the supervision and with the participation of management, including our Chief Executive Officer ("CEO") and Chief Financial Officer ("CFO"). The evaluation was conducted using the criteria set forth in Internal Control - Integrated Framework, issued by the Committee of Sponsoring Organizations of the Treadway Commission (the “COSO 2013 Framework”). Based upon this evaluation, our CEO and CFO concluded that, because of the material weaknesses in our ICFR described below, our DCP were not effective as of such date.

INTERNAL CONTROL OVER FINANCIAL REPORTING

NI 52-109 requires the CEO and CFO to certify that they are responsible for establishing and maintaining ICFR for the Company and that those internal controls have been designed and are effective in providing reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with IFRS. Similarly, Exchange Act Rule 13a-15(c) requires the Company's management, with the participation of the CEO and CFO, to evaluate ICFR as of the end of the fiscal year. The CEO and CFO are also responsible for disclosing any changes to the Company’s internal controls during the most recent period that have materially affected, or are reasonably likely to materially affect, its internal control over financial reporting.

MANAGEMENT’S DISCUSSION AND ANALYSIS | FOR THE THREE MONTHS ENDED DECEMBER 31, 2025 AND DECEMBER 31, 2024 14

LIMITATIONS ON SCOPE OF DESIGN

The Company has limited the scope of its evaluation of DCP and ICFR to exclude controls, policies and procedures over entities that were acquired by the Company not more than 365 days before the end of the financial period. The only entities controlled by the Company but that were scoped out of the evaluation of DCP and ICFR were CPL and Organigram USA Inc. (both acquired effective March 31, 2025).

Excluding goodwill and intangible assets, CPL constitutes approximately $2,523 of the Company’s current assets, $2,523 of total assets, $1,097 of current liabilities and $5,030 of total liabilities as of the acquisition date. As of the date of this MD&A, the purchase price allocation for CPL has not yet been finalized.

MATERIAL CHANGES TO INTERNAL CONTROL OVER FINANCIAL REPORTING

In compliance with reporting obligations, management is in the process of assessing the effectiveness of ICFR pertaining to the recently acquired entities, CPL and Organigram USA Inc. In Q1 Fiscal 2026 management, with oversight from the Audit Committee, implemented remediation measures related to the material weaknesses identified as at September 30, 2025 as outlined below in the "Status of Remediation Plan" section.

MANAGEMENT’S EVALUATION OF INTERNAL CONTROL OVER FINANCIAL REPORTING

The Company’s management, under the supervision and with the participation of its CEO and CFO, conducted an evaluation of the effectiveness of the Company’s ICFR as defined by NI 52-109 and Rule 13a-15(f) of the Exchange Act as of December 31, 2025, using the criteria set forth by the COSO 2013 Framework. Based on this evaluation, management concluded that the Company's ICFR was not effective as of December 31, 2025.

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis. Management has identified the following material weakness:

•Management review controls designed to ensure the completeness and accuracy of complex spreadsheets used in the biological assets and inventory valuation processes, as well as user access rights and related controls over the inventory management application Ample system, were not designed or operating effectively. The material weakness related to the inventory management application Ample system was remediated through the decommissioning of the system application in the Q1 Fiscal 2026, and the system application is no longer in use.

STATUS OF REMEDIATION PLAN

The Company made progress in remediating the material weakness related to IT General Controls and made progress in remediating other control deficiencies as discussed above under “Material Changes to Internal Control Over Financial Reporting” as at the end of Fiscal 2025. Management, with the assistance of external and internal specialists, has continued reviewing and revising its ICFR, and remains committed to implementing changes to its ICFR to ensure that the control deficiencies that contributed to the remaining material weakness is remediated in Fiscal 2026.

The following remedial activities remain in progress as at the date of this MD&A and are expected to continue at least throughout the first half of Fiscal 2026. The controls associated with these remedial activities have not yet been subject to control testing to conclude on the design or operational effectiveness.

•The Company will continue to streamline complex spreadsheet models related to biological assets and inventory to reduce the risk of errors in mathematical formulas and to improve the ability to verify the logic of complex spreadsheets, while continuing to automate processes, and leverage the Company's new inventory costing upgrades in its ERP system.

A component of the material weakness related to the inventory management application Ample system was remediated through the decommissioning of the system application in the first quarter of Fiscal 2026, and the system application is no longer in use. Similar controls within the new system have not yet been tested to determine their operating effectiveness.

Following the improvement of the material weakness related to IT General Controls, senior management has discussed the remaining material weakness with the Audit Committee which will continue to review progress on these remediation activities. While we believe these actions, including the third phase of the ERP system, will contribute to the remediation of the material weakness, we have not yet completed all of the corrective processes, procedures and related evaluation or remediation that we believe are necessary. As we continue to evaluate and work to remediate the remaining material weakness, we may need to take additional measures to address the deficiencies. Until the remediation steps set forth above, including the efforts to implement any additional control activities identified in the process, are fully implemented and operate for a sufficient period of time that they can be concluded to be operating effectively, the remaining material weakness described above will not be considered fully remediated. While significant progress has been made toward remediation of the remaining material weakness, no assurance can

MANAGEMENT’S DISCUSSION AND ANALYSIS | FOR THE THREE MONTHS ENDED DECEMBER 31, 2025 AND DECEMBER 31, 2024 15

be provided at this time that the actions and remediation efforts will effectively remediate the remaining material weakness described above or prevent the incidence of other material weaknesses in the Company’s ICFR in the future. Management expects to fully remediate the remaining material weakness identified before the end of Fiscal 2026. See “Risk Factors” in this MD&A and in the Company's annual information form for the year ended September 30, 2025 ("AIF").

Management, including the CEO and CFO, does not expect that DCP or ICFR will prevent all misstatements, even as the remediation measures are implemented and further improved to address the material weakness. The design of any system of internal controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving the stated goals under all potential future conditions.

MANAGEMENT’S DISCUSSION AND ANALYSIS | FOR THE THREE MONTHS ENDED DECEMBER 31, 2025 AND DECEMBER 31, 2024 16

RISK FACTORS

The Company’s business is subject to risks inherent in a high-growth, heavily regulated industry. We have identified certain risks pertinent to our business that may have affected or may affect our business, financial conditions, results of operations and cash flows, as further described in this MD&A. For additional risk factors, readers are directed to the discussion under "Risk Factors" in the AIF, which is (a) available under the Company’s issuer profile on SEDAR+ at www.sedarplus.com, and (b) incorporated into and forms part of the Company's annual report on Form-40F filed on EDGAR at www.sec.gov. Management attempts to assess and mitigate any risks and uncertainties by retaining experienced professional staff and ensuring that the Board of Directors and senior management of the Company are monitoring the risks impacting or likely to impact the business on a continuous basis.

(i) Credit Risk

Credit risk arises from deposits with banks, short-term investments, outstanding trade and other receivables, restricted cash and other financial assets. For trade receivables, the Company does not hold any collateral as security but mitigates this risk by dealing only with what management believes to be financially sound counterparties and, accordingly, does not anticipate significant loss for non-performance. For other receivables, outside of the normal course of business, management generally obtains guarantees and general security agreements. The maximum exposure to credit risk of cash, short-term investments, restricted cash, other financial assets and accounts receivable and other receivables on the statement of financial position at December 31, 2025 approximates $162,312 (September 30, 2025 – $198,827).

As of December 31, 2025 and September 30, 2025, the Company’s aging of trade receivables was as follows:


	DECEMBER 31, 2025		SEPTEMBER 30, 2025
0-90 days	$	38,568	$	56,442
More than 90 days	15,622		12,846
Gross trade receivables	$	54,190	$	69,288
Less: Expected credit losses and reserve for product returns and price adjustments	(5,118)		(5,703)
	$	49,072	$	63,585

(ii) Liquidity Risk

The Company’s liquidity risk is the risk that the Company will not be able to meet its financial obligations as they come due. The Company manages its liquidity risk by reviewing its capital requirements and liquidity position on an ongoing basis. At December 31, 2025, the Company had $7,576 (September 30, 2025 – $28,200) of cash (unrestricted) and working capital of $162,494 (September 30, 2025 – $158,738). Further, the Company may potentially access debt and/or equity capital through the capital markets if required, although there can be no assurance that capital will be available on terms acceptable to the Company or at all.

The Company is obligated to the following contractual maturities relating to their undiscounted cash flows as at December 31, 2025:


	Carrying Amount		Contractual Cash Flows		Less than 1 year		1 to 3 years		3 to 5 years		More than 5 years
Accounts payable and accrued liabilities	$	71,079	$	71,079	$	71,079	$	—	$	—	$	—
Long-term debt	10		10		10		0		—		—
Lease obligations	8,442		10,862		1,529		3,178		2,878		3,277
	$	79,531	$	81,951	$	72,618	$	3,178	$	2,878	$	3,277

The contractual maturities noted above are based on contractual due dates of the respective financial liabilities.

In connection with the Company’s facilities, the Company is contractually committed to approximately $925 of capital expenditures.

(iii) Market Risk

Market risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices. Market risk for the Company is comprised of interest rate risk, which is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company’s exposure to the risk of changes in market interest rates relates primarily to the Company’s debt obligations with a floating interest rate. The Company has determined that a 1% change in rates would not have a material impact on the consolidated financial statements.

MANAGEMENT’S DISCUSSION AND ANALYSIS | FOR THE THREE MONTHS ENDED DECEMBER 31, 2025 AND DECEMBER 31, 2024 17

(iv) Concentration Risk

The Company’s accounts receivable are primarily due from provincial government agencies (four of which, individually, represented more than 10% of the Company’s revenues during the three months ended December 31, 2025), with the remaining material accounts receivable balance due from an international customer. The provincial government agencies and the international customer are considered creditworthy, and management believes that the entire accounts receivable balance is collectible.

(v) Risks of significant changes or developments with respect to domestic and international customs, tariffs, and trade policies, corresponding or retaliatory actions by other countries and related uncertainties

Significant changes or developments with respect to domestic and international customs, tariffs, and trade policies in the geographies where the Company operates, any corresponding or retaliatory actions taken, and related uncertainties could have an adverse effect on the Company's financial results and profitability. Since the inauguration of the current U.S. president on January 20, 2025, the U.S. has imposed a number of tariffs on exports from Canada and other countries to the U.S. The international trade disputes sparked by the tariffs imposed or potential tariffs to be imposed by the U.S. and any other future actions taken by the U.S. and other countries in response, including a further escalation in tariffs, and/or the withdrawal from, or changes to, international trade agreements or policies related to international commerce, are expected to have a negative impact on the Canadian economy and other markets where the Company operates, and could adversely affect the Company’s business operations and financial condition. In addition, the uncertainty as to whether additional tariffs or trade policies will be adopted domestically or internationally and the uncertainty of the impact of such tariffs and trade policies have and may continue to have negative impact on the Canadian and global economy and may adversely affect the Company’s business operations and financial condition.

(vi) Risks related to third party data

The Company relies on independent third party data for market share position and there is no assurance third party data provides an accurate representation of actual sales as some third parties use different methodologies or calculations to estimate market share position, and because market and industry data is inherently imprecise, subject to interpretation and cannot be verified with complete certainty due to limits on the availability and reliability of raw data, the voluntary nature of the data gathering process, and other limitations and uncertainties inherent in any statistical survey or data collection process. The Company also relies on its own market research and internal data with the view to testing the reliability of such third-party data but the Company's ability to determine the accuracy of such third-party data remains limited.

(vii) Risks related to international sales and operations

The Company sells hemp-derived products in the U.S. and exports cannabis to a number of countries whose laws vary, and many are unsettled and still developing. There is no assurance that the Company will continue to meet the evolving legal and regulatory requirements applicable to each international jurisdiction. Any change in laws or regulations may adversely impact the Company’s ability to export its products or continue doing business in the U.S or any other international jurisdictions.

The Changing Legal Status of Hemp-Derived Products in the United States

The Company owns or invests in certain entities in the U.S, including a cannabis and hemp genetics licensing company and a hemp beverage company. While these entities currently comply with U.S. laws, such laws are frequently changing, and any widespread enforcement against the entities or the entities’ customers could negatively impact the Company’s business operations and financial condition.

In November 2025, the U.S. enacted the Continuing Appropriations and Extensions Act of 2026 (H.R. 5371), which includes a provision (section 781) to amend the definition of hemp in the 2018 Farm Bill to effectively eliminate hemp-derived THC products, although the change does not become effective for 365 days from the date of enactment. Organigram’s U.S. offerings would be directly impacted by this change in law; additionally, Organigram has investments in hemp seed and hemp ingredient manufacturers in the U.S. that may be impacted by this legislation. Efforts are underway to repeal, replace, or delay this amendment, but whether any change will occur is uncertain. If current federal legislation is not amended or reversed, Organigram may have to sell, wind-down or otherwise restructure its hemp THC product related activities in the U.S. by November 2026. In addition to federal uncertainty, unforeseen regulatory obstacles or compliance costs may hinder our ability to successfully compete in the market for such products, which could adversely impact our business, operating results, financial condition, brand and reputation.

The Company competes with other hemp THC products, state-legal cannabis products and products available in the illicit market, and the public is often uninformed about the differences of these markets. We test all of our products for safety and quality. However, many of our competitors in the market may not do so. Because our business is dependent, in part, upon continued market acceptance of THC by consumers, any negative trends relating to cannabis or hemp could adversely affect our business operations. For example, consumers may hear about negative health or safety outcomes for a competitor’s product and ascribe those outcomes to the entire category. Negative views of the category caused by third parties may hinder our ability to

MANAGEMENT’S DISCUSSION AND ANALYSIS | FOR THE THREE MONTHS ENDED DECEMBER 31, 2025 AND DECEMBER 31, 2024 18

successfully market our products, or lead to new laws or regulations that prohibit or limit the sale of such products, which could adversely impact our business, operating results, financial condition, brand and reputation.

On December 18, 2025, President Trump issued an Executive Order directing that cannabis be rescheduled from schedule I to schedule III. The Order directs the Attorney General to "take all necessary steps to complete the rulemaking process related to rescheduling marijuana to Schedule III of the Controlled Substances Act in the most expeditious manner. That would represent a significant, formal acknowledgement that cannabis has medical value and less potential for abuse than schedule I and II controlled substances. However, the timing of any rescheduling remains unknown, and any final order and administrative rules are likely to be challenged through litigation, and rescheduling could be delayed or ultimately denied. Furthermore, even if the U.S. does reschedule cannabis to schedule III, cannabis would remain a controlled substance and be subject to the CSA’s requirements including registration with the Drug Enforcement Administration (“DEA”). Accordingly, the state regulated cannabis programs as they exist today would still be federally illegal. Organigram does not intend to participate in the state cannabis programs unless and until doing so is no longer federally illegal or with the implementation of an appropriate structure. Furthermore, the rescheduling, in conjunction with certain amendments to the definition of hemp set to take effect in November 2026, would prohibit certain hemp products or subject them to more stringent restrictions than those currently in place.

A rescheduling may have other far reaching implications that are not yet fully understood, including for hemp and hemp THC products. In addition to directing rescheduling, the Executive Order also discusses a newly proposed pilot program where CMS (Centers for Medicare & Medicaid Services), through CMMI (Center for Medicare & Medicaid Innovation), will be able to cover the costs for certain cannabinoid based hemp therapies for seniors. Additional details for this program and its requirements are still pending, and it is uncertain whether the Company would be able to participate or whether the pilot program will drive additional competition from the pharmaceutical or other industries. The Executive Order also directs White House staff to work with Congress to “update the statutory definition” of hemp to allow Americans to access CBD products while permitting Congress to “restrict the sale of products posing serious health risks,” and to consult with relevant executive branch departments to “develop a regulatory framework for hemp-derived cannabinoid products, including development of guidance on an upper limit on milligrams of THC per serving with considerations on per container limits and CBD to THC ratio requirements.” It is unclear how this will be achieved, and whether Congress—which just revised the definition of hemp in the Continuing Appropriations and Extensions Act to permit no more than 0.4 milligrams of THC per container—will agree to further changes. All of this regulatory volatility creates significant uncertainty for our business of selling hemp THC products and our other U.S. hemp-related investments.

(ix) Information Systems Risk

During fiscal year 2023, Fiscal 2024 and Fiscal 2025, the Company launched a new ERP system, which provides for a more robust and secure financial system of record, among other supply chain and operational data. Various IT general controls are now centralized currently in the midst of stabilizing a new ERP system, which replaces its previous financial system. There can be no assurance that the ERP system will provide the information and benefits expected by management.

The stabilization of the ERP system requires an investment of significant personnel and financial resources, including substantial expenditures for outside consultants, cloud computing and software costs, in addition to other expenses in connection with the transformation of the Company's organizational structure and financial and operating processes. The stabilization of the new ERP system may result in delays, increased costs and other difficulties, including potential design defects, miscalculations, testing requirements, and the diversion of management’s attention from day-to-day business operations. If it is unable to stabilize the new ERP system as planned, the effectiveness of the internal control over financial reporting could be adversely affected, the ability to assess those controls adequately and to disseminate its financial documents could be delayed, the Company’s operations could be affected and the Company’s financial condition, results of operations and cash flows could be negatively impacted.

MANAGEMENT’S DISCUSSION AND ANALYSIS | FOR THE THREE MONTHS ENDED DECEMBER 31, 2025 AND DECEMBER 31, 2024 19

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION

Certain information herein contains or incorporates comments that constitute forward-looking information within the meaning of applicable securities legislation (“forward-looking information”). Forward-looking information, in general, can be identified by the use of forward-looking terminology such as “outlook”, “objective”, “may”, “will”, “could”, “would”, “might”, “expect”, “intend”, “estimate”, “anticipate”, “believe”, “plan”, “continue”, “budget”, “schedule” or “forecast” or similar expressions suggesting future outcomes or events. They include, but are not limited to, statements with respect to expectations, forecasts or other characterizations of future events or circumstances, and the Company’s objectives, goals, strategies, beliefs, intentions, plans, estimates, projections and outlook, including statements relating to the Company’s plans and objectives, or estimates or predictions of actions of customers, suppliers, partners, distributors, competitors or regulatory authorities; and statements regarding the Company’s future economic performance. These statements are not historical facts but instead represent management beliefs regarding future events, many of which by their nature are inherently uncertain and beyond management control. Forward-looking information in this MD&A is based on the Company’s current expectations about future events.

Certain forward-looking information in this MD&A includes, but is not limited to the following:

•Expectations regarding production capacity, including seed-based cultivation, capability of the beverage manufacturing line, facility size, THC content, costs and yields;

•Expectations regarding the prospects of the Company’s collaboration and investment transaction with BAT;

•Expectations regarding the prospects for the Company’s primary operating subsidiary, Organigram Inc.;

•Expectations around demand for cannabis and related products, future opportunities and sales, including the relative mix of medical versus recreational cannabis products, the relative mix of products within the recreational category;

•Changes in legislation related to permitted cannabis types, forms, and potency, and legislation of additional cannabis types and forms for adult use recreational cannabis in Canada, including regulations relating thereto, the timing and the implementation thereof, and our future product forms;

•Expectations around branded cannabis products with respect to timing, launch, product attributes, composition and consumer demand;

•Expectations around the revenue growth from innovative products, particularly the commercialization of its new FASTTM nanoemulsion technology;

•The scope of protection the Company is able to establish and maintain, if any, for its intellectual property ("IP") rights;

•Strategic investments and capital expenditures, and expected related benefits;

•Expectations regarding the Company's investments in OBX, Phylos and Sanity Group;

•Expectations regarding EU-GMP certification, including successful completion of the audit and follow-on correspondence with the regulator and timing for the issuance of the certification, if successful;

•The general continuance of current, or where applicable, assumed industry conditions;

•Changes in laws, regulations, guidelines, and policies, and the interpretation thereof, including those relating to the recreational and/or medical cannabis markets domestically and internationally, minor cannabinoids and environmental programs;

•The price of cannabis and derivative cannabis products;

•The impact of the Company’s cash flow and financial performance on third parties, including its supply partners;

•Fluctuations in the price of Common Shares and the market for Common Shares;

•The treatment of the Company's business under international regulatory regimes and impacts on changes thereto on the Company's international sales;

•The Company’s growth strategy, targets for future growth and forecasts of the results of such growth;

•Expectations concerning access to capital and liquidity, and the Company’s ability to access the public markets from time to time to fund operational activities and growth;

•Expectations concerning the Company's financial position, future liquidity and other financial results;

•The ability of the Company to generate cash flow from operations and from financing activities;

•The competitive conditions of the industry, including the Company’s ability to maintain or grow its market share;

•Expectations regarding the Company's ability to generate cost savings from operational effectiveness and automation initiatives;

•Expectations regarding capital expenditures and timing thereof; and

•Expectations concerning the Company's performance during the full-year fiscal 2026, including with respect to revenue, adjusted gross margin, selling, general and administrative expenses, adjusted EBITDA free cash flow, and cash from operations before working capital changes.

Forward-looking information is provided for the purposes of assisting the reader in understanding the Company and its business, operations, risks, financial performance, financial position and cash flows as at and for the periods ended on certain dates, and to present information about management’s current expectations and plans relating to the future, and the reader is cautioned that such statements may not be appropriate for other purposes. In addition, this MD&A may contain forward-looking information attributed to third party industry sources. Undue reliance should not be placed on forward-looking information, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. Forward-looking information does not guarantee future performance and involves known and unknown risks, uncertainties and other factors that may cause actual

MANAGEMENT’S DISCUSSION AND ANALYSIS | FOR THE THREE MONTHS ENDED DECEMBER 31, 2025 AND DECEMBER 31, 2024 20

results or events to differ materially from those anticipated in the forward-looking information. By its nature, forward-looking information involves numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the expectations, predictions, forecasts, projections and conclusions will not occur or prove accurate, that assumptions may not be correct, and that objectives, strategic goals and priorities will not be achieved. These and other factors may cause actual results or events to differ materially from those anticipated in the forward-looking information.

Factors that could cause actual results to differ materially from those set forth in forward-looking information include, but are not limited to: financial risks; cyber security risks; dependence on senior management and other key personnel, the Board, consultants and advisors; availability and sufficiency of insurance including continued availability and sufficiency of director and officer and other forms of insurance; the Company and its subsidiaries being able to, where applicable, cultivate cannabis pursuant to applicable law and on the currently anticipated timelines and in anticipated volumes; industry competition; global events, including heightened economic and industry uncertainty as a result of any pandemic or epidemic and governmental action in respect thereto, including with respect to impacts on production, operations, disclosure controls and procedures or internal control over financial reporting, and supply chain and distribution disruptions; facility and technological risks; changes to government laws, regulations or policy, including the amendment of the definition of hemp in the 2018 Farm Bill to effectively eliminate hemp-derived THC products, environmental or tax, or the enforcement thereof; agricultural risks; ability to maintain any required licenses or certifications; supply risks; product risks; construction delays or postponements; packaging and shipping logistics; inflationary risk, expected number of medical and recreational cannabis users in Canada and internationally; continuation of shipments to existing and prospective international jurisdictions and customers; potential time frame for the implementation of legislation to legalize cannabis internationally; the Company’s, its subsidiaries' and its investees’ ability to, where applicable, obtain and/or maintain their status as LP or other applicable licensees; risk factors affecting its investees; availability of any required financing on commercially acceptable terms or at all; the potential size of the regulated recreational cannabis market in Canada; demand for and changes in the Company’s cannabis and related products, including the Company’s derivative products, and the sufficiency of the retail networks to supply such demand; ability to enter and participate in international market opportunities; general economic, financial market, regulatory, industry and political conditions affecting the Company; the ability of the Company to compete in the cannabis industry and changes in the competitive landscape; a material decline in cannabis prices; the Company’s ability to manage anticipated and unanticipated costs; the Company’s ability to implement and maintain effective internal control over financial reporting and disclosure controls and procedures; risks relating to potential failure of the Company's IT system; ongoing expansions to the Company's ERP system; continuing to meet listing standards for the TSX and the NASDAQ; risks relating to the Company's IP; liquidity risk; concentration risk; and other risks and factors described from time to time in the documents filed by the Company with securities regulators in Canada and the United States. Material factors and assumptions used in establishing forward-looking information include that production activities will proceed as planned, and demand for cannabis and related products will change in the manner expected by management. All forward-looking information is provided as of the date of this MD&A.

Certain forward-looking information included herein may also constitute a "financial outlook" within the meaning of applicable securities legislation. Financial outlook involves statements about the Company's prospective financial performance and financial position that are based on and subject to the assumptions about future economic conditions and courses of action described above as well as management's expectations regarding a strong innovation pipeline, increasing international sales, high cannabis quality and higher potency, commercialization of FAST nano-emulsion technology in ingestible formats, and receipt of the EU-GMP certification. Such assumptions are based on management's assessment of the relevant information currently available and any financial outlook included herein is provided for the purpose of helping readers understand management's current expectations and plans for the future as of the date hereof. The actual results of the Company's operations may vary from the amounts set forth in any financial outlook and such variances may be material. Readers are cautioned that reliance on any financial outlook may not be appropriate for other purposes, or in other circumstances and that the risk factors described above and other factors may cause actual results to differ materially from any financial outlook.

The Company does not undertake to update any such forward-looking information whether as a result of new information, future events or otherwise, except as required by law.

ADDITIONAL INFORMATION ABOUT THE ASSUMPTIONS, RISKS AND UNCERTAINTIES OF THE COMPANY’S BUSINESS AND MATERIAL FACTORS OR ASSUMPTIONS ON WHICH INFORMATION CONTAINED IN FORWARD-LOOKING INFORMATION IS BASED IS PROVIDED IN THE COMPANY’S DISCLOSURE MATERIALS, INCLUDING IN THIS MD&A UNDER “RISK FACTORS” AND THE COMPANY’S CURRENT AIF UNDER “RISK FACTORS”, FILED WITH THE SECURITIES REGULATORY AUTHORITIES IN CANADA AND AVAILABLE UNDER THE COMPANY’S ISSUER PROFILE ON SEDAR+ AT WWW.SEDARPLUS.CA, AND FILED WITH OR FURNISHED TO THE SEC AND AVAILABLE ON EDGAR AT WWW.SEC.GOV. ALL FORWARD-LOOKING INFORMATION IN THIS MD&A IS QUALIFIED BY THESE CAUTIONARY STATEMENTS.

CAUTIONARY STATEMENT REGARDING CERTAIN NON-IFRS MEASURES

This MD&A contains certain financial and operational performance measures that are not recognized or defined under IFRS (i.e. non-IFRS measures). As there are no standardized methods of calculating these non-IFRS measures, the Company's approaches may differ from those used by others and this data may not be comparable to similar data presented by other LPs and cannabis

MANAGEMENT’S DISCUSSION AND ANALYSIS | FOR THE THREE MONTHS ENDED DECEMBER 31, 2025 AND DECEMBER 31, 2024 21

companies. For an explanation of these measures to related comparable financial information presented in the Financial Statements prepared in accordance with IFRS, refer to the discussion below.

The Company believes that these non-IFRS measures are useful indicators of operating performance and are specifically used by management to assess the financial and operating performance of the Company. These non-IFRS measures include, but are not limited to, the following:

•Adjusted gross margin is calculated by subtracting cost of sales, before the effects of: (i) unrealized gain on changes in fair value of biological assets; (ii) realized fair value on inventories sold and other inventory charges; (iii) realized fair value on inventories sold from acquisitions; (iv) provisions and impairment of inventories and biological assets; and (v) provisions to net realizable value. Adjusted gross margin percentage is calculated by dividing adjusted gross margin by net revenue. Adjusted gross margin is reconciled to the most directly comparable IFRS financial measure in the "Financial Results and Review of Operations" section of this MD&A.

Management believes that these measures provide useful information to assess the profitability of our operations as they represent the normalized gross margin generated from operations and exclude the effects of non-cash fair value adjustments on inventories and biological assets, which are required by IFRS. The most directly comparable measure to adjusted gross margin calculated in accordance with IFRS is gross margin before fair value adjustments.

•Adjusted EBITDA is calculated as net income (loss) excluding: financing costs, net of investment income; income tax expense (recovery); depreciation, amortization, impairment, normalization of depreciation add-back due to changes in depreciable assets resulting from impairment charges, (gain) loss on disposal of property, plant and equipment (per the consolidated statement of cash flows); share-based compensation (per the consolidated statement of cash flows); share of loss (gain) from investments in associates including impairment loss; change in fair value of contingent consideration; change in fair value of derivative liabilities, other financial assets and preferred shares; expenditures incurred in connection with research and development activities (net of depreciation); unrealized gain on changes in fair value of biological assets; realized fair value on inventories sold and other inventory charges; provisions and net realizable value adjustments related to inventory and biological assets; government subsidies, insurance recoveries and other non-operating expenses (income); legal provisions (recoveries); ERP implementation costs; transaction costs; share issuance costs; and provision for Canndoc (as defined herein) expected credit losses. Adjusted EBITDA is reconciled to the most directly comparable IFRS financial measure in the "Financial Results and Review of Operations" section of this MD&A.

During the second quarter of Fiscal 2024, management changed the calculation of adjusted EBITDA and has conformed prior quarters accordingly to include provision for expected credit losses.

Adjusted EBITDA is intended to provide a proxy for the Company’s operating cash flow and derives expectations of future financial performance for the Company, and excludes adjustments that are not reflective of current operating results. The most directly comparable measure to adjusted EBITDA calculated in accordance with IFRS is net income (loss).

•Free cash flow provided by (used in) operating activities is calculated as net cash provided by or used in operating activities less the purchase of property, plant and equipment. Free cash flow is reconciled to the most directly comparable IFRS financial measure in the "Balance Sheet, Liquidity and Capital Resources" section of this MD&A.

Free cash flow is a useful indicator of the Company's capacity to fund operations from internally generated cash flows, without the need for additional borrowings or use of existing cash reserves under normal operating conditions. The most directly comparable measure to free cash flow calculated in accordance with IFRS is net cash and restricted cash provided by (used in) operating activities.

Non-IFRS measures should be considered together with other data prepared in accordance with IFRS to enable investors to evaluate the Company’s operating results, underlying performance and prospects in a manner similar to the Company’s management. Accordingly, these non-IFRS measures are intended to provide additional information and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with IFRS.

MANAGEMENT’S DISCUSSION AND ANALYSIS | FOR THE THREE MONTHS ENDED DECEMBER 31, 2025 AND DECEMBER 31, 2024 22


TABLE OF CONTENTS


Condensed Consolidated Interim Statements of Financial Position			1
Condensed Consolidated Interim Statements of Operations and Comprehensive Income (Loss)			2
Condensed Consolidated Interim Statements of Changes in Equity			3
Condensed Consolidated Interim Statements of Cash Flows			4
Notes to the Condensed Consolidated Interim Financial Statements	5	–	16

ORGANIGRAM GLOBAL INC.

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION

As at December 31, 2025 and September 30, 2025

(Unaudited - expressed in CDN $000’s except share and per share amounts)


	DECEMBER 31, 2025		SEPTEMBER 30, 2025
ASSETS
Current assets
Cash	$	7,576	$	28,200
Short-term investments	805		826
Restricted cash (Note 4)	54,585		55,394
Accounts and other receivables (Note 5)	49,941		64,859
Biological assets (Note 6)	16,490		17,931
Inventories (Note 7)	116,221		106,023
Prepaid expenses and deposits	10,927		11,664
	256,545		284,897

Property, plant and equipment (Note 8)	123,482		122,977
Intangible assets	46,743		48,511
Goodwill	52,524		52,524
Deferred charges and deposits	1,974		3,754
Other financial assets (Note 9)	49,405		49,548


	$	530,673	$	562,211

LIABILITIES
Current liabilities
Accounts payable and accrued liabilities	$	71,079	$	89,247

Derivative liabilities (Note 10)	16,705		28,832
Other liabilities (Note 11)	6,267		8,080
	94,051		126,159


Derivative liabilities (Note 10)	4,644		5,506
Preferred shares (Note 12)	55,017		68,653

Other long-term liabilities (Note 11)	7,505		12,763
	161,217		213,081

SHAREHOLDERS' EQUITY
Share capital (Note 13)	921,612		919,908
Equity reserves	36,418		37,346
Accumulated other comprehensive income	184		603
Accumulated deficit	(588,758)		(608,727)
	369,456		349,130
	$	530,673	$	562,211

On behalf of the Board:

/s/James Yamanaka, Director

/s/Peter Amirault, Director

The accompanying notes are an integral part of these Condensed Consolidated Interim Financial Statements.

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED) | FOR THE THREE MONTHS ENDED DECEMBER 31, 2025 AND 2024 1

ORGANIGRAM GLOBAL INC.

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)

For the three months ended December 31, 2025 and 2024

(Unaudited - expressed in CDN $000’s except share and per share amounts)


	THREE MONTHS ENDED
		DECEMBER 31, 2025		DECEMBER 31, 2024
REVENUE
Gross revenue (Note 17)		$	97,298	$	66,806
Excise taxes		(33,760)		(24,076)
Net revenue		63,538		42,730
Cost of sales		40,021		28,615
Gross margin before fair value adjustments		23,517		14,115
Realized fair value on inventories sold and other inventory charges (Note 7)		(16,911)		(13,066)
Unrealized gain on changes in fair value of biological assets (Note 6)		16,709		12,765
Gross margin		23,315		13,814

OPERATING EXPENSES
General and administrative (Note 18)		14,950		11,233
Sales and marketing		8,991		5,804
Research and development		2,084		2,369
Share-based compensation		708		1,209


Total operating expenses		26,733		20,615

LOSS FROM OPERATIONS		(3,418)		(6,801)
Investment income, net of financing costs		(93)		(825)
Acquisition and transaction costs		1,606		4,504


Change in fair value of contingent consideration		(1,809)		—
Change in fair value of derivative liabilities, preferred shares and other financial assets (Note 16)		(24,392)		14,495

Other non-operating expense, net		1,301		(2,018)




NET INCOME (LOSS)		19,969		(22,957)

OTHER COMPREHENSIVE INCOME (LOSS)
Change in fair value of investments at fair value through other comprehensive income (loss) (Note 9)		(419)		240

COMPREHENSIVE INCOME (LOSS)		$	19,550	$	(22,717)

Net earnings (loss) per common share, basic		$	0.148	$	(0.202)
Net earnings (loss) per common share, diluted		$	0.146	$	(0.202)

The accompanying notes are an integral part of these Condensed Consolidated Interim Financial Statements.

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED) | FOR THE THREE MONTHS ENDED DECEMBER 31, 2025 AND 2024 2

ORGANIGRAM GLOBAL INC.

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN EQUITY

For the three months ended December 31, 2025 and December 31, 2024

(Unaudited - expressed in CDN $000’s except share and per share amounts)


	NUMBER OF SHARES	SHARE CAPITAL		EQUITY RESERVES		ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)		ACCUMULATED DEFICIT		SHAREHOLDERS' EQUITY
Balance - October 1, 2024	108,585,492	$	852,891	$	37,129	$	(63)	$	(583,968)	$	305,989

Private placement	17,233,950	39,050		—		—		—		39,050

Share-based compensation	—	—		1,325		—		—		1,325

Exercise of restricted share units	337,231	653		(653)		—		—		—



Net loss	—	—		—				(22,957)		(22,957)
Other comprehensive income	—	—		—		240		—		240
Balance - December 31, 2024	126,156,673	$	892,594	$	37,801	$	177	$	(606,925)	$	323,647

Balance - October 1, 2025	134,461,029	$	919,908	$	37,346	$	603	$	(608,727)	$	349,130



Share-based compensation (Note 13)	—	—		770		—		—		770
Exercise of stock options (Note 13)	3,350	11		(5)		—		—		6
Exercise of restricted share units (Note 13)	579,918	1,255		(1,255)		—		—		—
Exercise of performance share units (Note 13)	88,485	438		(438)		—		—		—


Net income	—	—		—		—		19,969		19,969
Other comprehensive loss	—	—		—		(419)		—		(419)
Balance - December 31, 2025	135,132,782	$	921,612	$	36,418	$	184	$	(588,758)	$	369,456

The accompanying notes are an integral part of these Condensed Consolidated Interim Financial Statements.

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED) | FOR THE THREE MONTHS ENDED DECEMBER 31, 2025 AND 2024 3

ORGANIGRAM GLOBAL INC.

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS

For the three months ended December 31, 2025 and 2024

(Unaudited - expressed in CDN $000’s except share and per share amounts)


	THREE MONTHS ENDED
		DECEMBER 31, 2025		DECEMBER 31, 2024
CASH USED IN
OPERATING ACTIVITIES
Net income (loss)		$	19,969	$	(22,957)
Items not affecting operating cash:
Share-based compensation (Note 13)		770		1,325
Depreciation and amortization		4,980		3,387



Realized fair value on inventories sold and other inventory charges (Note 7)		16,911		13,066
Unrealized gain on changes in fair value of biological assets (Note 6)		(16,709)		(12,765)
Investment income, net of financing costs		(93)		(825)

Change in fair value of contingent consideration		(1,809)		—


Change in fair value of derivative liabilities, preferred shares and other financial assets (Note 16)		(24,392)		14,495
Unrealized foreign exchange loss (gain)		626		(2,014)


Cash and restricted cash provided by (used in) operating activities before working capital changes		253		(6,288)
Changes in non-cash working capital:
Net change in accounts and other receivables, biological assets, inventories, prepaid expenses and deposits		6,649		13,667


Net change in accounts payable and accrued liabilities, provisions and other liabilities		(22,915)		(11,559)




Net cash and restricted cash used in operating activities		(16,013)		(4,180)

FINANCING ACTIVITIES






Payment of lease liabilities, net of sublease receipts		(441)		(187)
Payment of long-term debt		(15)		(15)

Stock options exercised		6		—

Net cash used in financing activities		(450)		(202)

INVESTING ACTIVITIES
Purchase of short-term investments		(800)		(1,659)
Proceeds from short-term investments		826		—
Acquisition of subsidiary, net of cash acquired		—		(59,164)
Investment income		244		905

Other financial assets		(2,510)		—

Purchase of property, plant and equipment (Note 8)		(2,104)		(1,626)
Purchase of intangible assets		—		(9)
Net cash used in investing activities		(4,344)		(61,553)

Effect of foreign exchange on cash		(626)		2,014
DECREASE IN CASH AND RESTRICTED CASH		(21,433)		(63,921)

CASH AND RESTRICTED CASH
Beginning of period		83,594		132,605
End of period		$	62,161	$	68,684

Less: restricted cash		(54,585)		(24,386)
Cash as presented on the statement of financial position		$	7,576	44,298

The accompanying notes are an integral part of these Condensed Consolidated Interim Financial Statements.

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED) | FOR THE THREE MONTHS ENDED DECEMBER 31, 2025 AND 2024 4

ORGANIGRAM GLOBAL INC.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the three months ended December 31, 2025 and December 31, 2024

(Unaudited - expressed in CDN $000’s except share and per share amounts)

1. NATURE OF OPERATIONS

Organigram Global Inc. (formerly known as "Organigram Holdings Inc.") (the “Company”) is a publicly listed corporation with its common shares (the “Common Shares”) trading on the Toronto Stock Exchange (“TSX”) and on the Nasdaq Global Select Market (“NASDAQ”) under the symbol “OGI”. The head office of the Company is 1400-145 King Street West, Toronto, Ontario, Canada, M5H 1J8 and the registered office is 35 English Drive, Moncton, New Brunswick, Canada, E1E 3X3.

On March 24, 2025, the shareholders of the Company at the annual and special meeting of shareholders approved an amendment to the articles of the Company to change the name of the Company to “Organigram Global Inc". On March 31, 2025, the Company obtained all regulatory approvals for the change of name of the Company.

The Company’s wholly-owned subsidiaries are: (i) Organigram Inc., a licensed producer (“LP” or “Licensed Producer”) of cannabis and cannabis-derived products in Canada regulated by Health Canada under the Cannabis Act (Canada) and the Cannabis Regulations (Canada); (ii) 10870277 Canada Inc., a special purpose holding company for the Company; and (iii) Organigram USA Inc. (formerly known as Collective Project USA Limited) ("OGI USA"), a wholly-owned subsidiary of Organigram Inc. The Company was incorporated under the Business Corporations Act (British Columbia) on July 5, 2010, and continued under the Canada Business Corporations Act (“CBCA”) on April 6, 2016. Organigram Inc. was incorporated under the Business Corporations Act (New Brunswick) on March 1, 2013. 10870277 Canada Inc. was incorporated under the CBCA on July 4, 2018. OGI USA was incorporated under the General Corporation Law of the State of Delaware on April 12, 2019.

On October 1, 2023, Organigram Inc. amalgamated with the Company's then wholly-owned subsidiaries, The Edibles and Infusions Corporation ("EIC") and Laurentian Organic Inc. ("Laurentian"), and continued as a single corporation under the name "Organigram Inc.", a 100% owned subsidiary of the Company. EIC was incorporated under the Business Corporations Act (Ontario) on September 20, 2018. Laurentian was incorporated under the CBCA on March 18, 2019.

On April 1, 2025, Organigram Inc. amalgamated with the Company's then wholly-owned subsidiary, Motif Labs Ltd. ("Motif") and continued as a single corporation under the name "Organigram Inc.", a 100% owned subsidiary of the Company. Motif was incorporated under the Business Corporations Act (Ontario) on December 18, 2017.

On October 1, 2025, Organigram Inc. amalgamated with the Company's then wholly-owned subsidiary, Collective Project Limited (“CPL”) and continued as a single corporation under the name "Organigram Inc.", a 100% owned subsidiary of the Company. CPL was incorporated under the CBCA on October 23, 2013.

2. BASIS OF PREPARATION

i.Statement of compliance

These unaudited condensed consolidated interim financial statements ("interim financial statements") have been prepared in accordance with International Accounting Standard 34 (“IAS 34”) - Interim Financial Reporting as issued by the International Accounting Standards Board (“IASB”). The interim financial statements should be read in conjunction with the audited consolidated financial statements of the Company for the years ended September 30, 2025 and 2024 (“Annual Consolidated Financial Statements”), which have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the IASB.

These interim financial statements were approved and authorized for issue by the Board of Directors of the Company on February 5, 2026.

ii.Basis of measurement

These interim financial statements have been prepared on a historical cost basis except for biological assets, share-based compensation, contingent share consideration, short-term investments, preferred shares, other financial assets and derivative liabilities, which are measured at fair value.

Historical cost is the fair value of the consideration given in exchange for goods and services, which is generally based upon the fair value of the consideration given in exchange for assets at the time of the transaction.

iii.Basis of consolidation

These interim financial statements include the accounts of the Company and its subsidiaries on a consolidated basis after elimination of intercompany transactions and balances. Subsidiaries are entities the Company controls when it is exposed, or has rights, to variable returns from its involvement and has the ability to affect those returns through its power to direct the relevant activities of the subsidiaries. The results of subsidiaries acquired during the year are consolidated from the date of acquisition.

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED) | FOR THE THREE MONTHS ENDED DECEMBER 31, 2025 AND 2024 5

Associates are all entities over which the Company has significant influence but not control or joint control. Investments in associates are accounted for using the equity method after initial recognition at cost. Joint operations are arrangements in which the Company has joint control. The Company includes its proportionate share of the assets acquired and expenses incurred of the joint operation.

iv.Foreign currency translation

Functional and presentation currency

These interim financial statements are presented in Canadian dollars, which is the functional currency of the Company and its subsidiaries, except for one subsidiary (OGI USA) and an associate (Alpha-Cannabis Pharma GmbH), for which the functional currencies have been determined to be United States dollars and Euros, respectively.

3. MATERIAL ACCOUNTING POLICIES

The accounting policies adopted in the preparation of the interim financial statements are consistent with those followed in the preparation of the Company’s Annual Consolidated Financial Statements, except for the adoption of the following new standards and amendments.

New and amended accounting standards

These amendments do not have any material impact on the Company’s consolidated financial statements.

Critical accounting estimates and judgments

The preparation of the Company’s financial statements requires management to make estimates, assumptions and judgments that affect the application of accounting policies, and the reported amounts of assets, liabilities, revenues and expenses. Significant estimates and judgments used in preparation of the interim financial statements are described in the Company’s Annual Consolidated Financial Statements.

4. RESTRICTED CASH

As at December 31, 2025, the Company held restricted cash balances of $54,585 (September 30, 2025 - $55,394). These balances represent proceeds received under the product development collaboration agreement dated March 10, 2021, and the subscription agreement dated November 5, 2023, with BT DE Investments Inc., a wholly-owned subsidiary of British American Tobacco p.l.c ("BAT"), and are subject to contractual restrictions that limit their use for general corporate purposes. Accordingly, these amounts are presented separately in the consolidated statements of financial position and excluded from cash and cash equivalents in the consolidated statements of cash flows.

5. ACCOUNTS AND OTHER RECEIVABLES

The Company’s accounts and other receivables include the following balances as at December 31, 2025 and September 30, 2025:


	DECEMBER 31, 2025		SEPTEMBER 30, 2025
Gross trade receivables	$	54,190	$	69,288
Less: reserves for product returns and price adjustments	(224)		(734)
Less: expected credit losses	(4,894)		(4,969)
Trade receivables	49,072		63,585
Receivable from related party	848		701

Current portion of net investment in subleases	12		12
Other receivables	9		561
	$	49,941	$	64,859

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED) | FOR THE THREE MONTHS ENDED DECEMBER 31, 2025 AND 2024 6

6. BIOLOGICAL ASSETS

The Company measures biological assets, which consist of cannabis plants, at fair value less costs to sell up to the point of harvest, which then becomes the basis for the cost of finished goods inventories after harvest. Subsequent expenditures incurred on these finished goods inventories after harvest are capitalized based on IAS 2 - Inventories.

The changes in the carrying value of biological assets as at December 31, 2025 are as follows:


	CAPITALIZED COST		BIOLOGICAL ASSET FAIR VALUE ADJUSTMENT		AMOUNT




Balance, September 30, 2025	$	6,032	$	11,899	$	17,931

Unrealized gain on changes in fair value of biological assets	—		16,709		16,709
Production costs capitalized	12,911		—		12,911
Transfer to inventory upon harvest	(9,668)		(21,393)		(31,061)
Balance, December 31, 2025	$	9,275	$	7,215	$	16,490

The fair value less costs to sell of biological assets is determined using a model which estimates the expected harvest yield in grams for plants currently being cultivated, then adjusts that amount for the average selling price per gram, and for any additional costs to be incurred, such as post-harvest costs. The following unobservable inputs, all of which are classified as level 3 within the fair value hierarchy (see Note 16), are used in determining the fair value of biological assets:

i.average selling price per gram – calculated as the weighted average current selling price of cannabis sold by the Company, adjusted for expectations about future pricing;

ii.expected average yield per plant – represents the number of grams of finished cannabis inventory which is expected to be obtained from each harvested cannabis plant currently under cultivation;

iii.wastage of plants based on their various stages of growth – represents the weighted average percentage of biological assets which are expected to fail to mature into cannabis plants that can be harvested;

iv.post-harvest costs – calculated as the cost per gram of harvested cannabis to complete the sale of cannabis plants post-harvest, consisting of the cost of direct and indirect materials and labour related to drying, labelling, and packaging; and

v.stage of completion in the cultivation process – calculated by taking the average number of weeks in production over a total average grow cycle of approximately 14 weeks.

The Company estimates the harvest yields for the cannabis on plants at various stages of growth, based on expected yield of mature plants. As of December 31, 2025, it is expected that the Company’s biological assets will yield 40,635 kg (September 30, 2025 – 35,108 kg) of cannabis when eventually harvested. The Company’s estimates are, by their nature, subject to change, and differences from the expected yield will be reflected in the fair value adjustment to biological assets in future periods. The Company accretes fair value on a straight-line basis according to stage of growth. As a result, a cannabis plant that is 50% through its 14-week growing cycle would be ascribed approximately 50% of its harvest date expected fair value less costs to sell (subject to wastage adjustments). Management believes the most significant unobservable inputs and their impact on fair value are as follows:


SIGNIFICANT	WEIGHTED AVERAGE INPUT							EFFECT ON FAIR VALUE
INPUTS & ASSUMPTIONS	December 31, 2025			September 30, 2025			SENSITIVITY	December 31, 2025		September 30, 2025
Average selling price per gram (excluding trim)	$	1.68		$	1.78		Increase or decrease by 10% per gram	$	1,602	$	1,756
Expected average yield per plant	204		grams	188		grams	Increase or decrease by 10 grams	$	784	$	946

The expected average yield per plant at December 31, 2025 and September 30, 2025 primarily reflects the average yield of the flower component of the plant.

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED) | FOR THE THREE MONTHS ENDED DECEMBER 31, 2025 AND 2024 7

7. INVENTORIES

The Company’s inventories are comprised of the following balances as at December 31, 2025 and September 30, 2025:


	December 31, 2025
	CAPITALIZED COST		FAIR VALUE ADJUSTMENT		CARRYING VALUE
Plants in drying stage	$	2,399	$	711	$	3,110
Dry cannabis
Available for packaging	26,859		26,009		52,868
Packaged inventory	4,064		42		4,106
Flower and trim available for extraction	4,237		3,311		7,548
Concentrated extract	6,728		785		7,513
Formulated extracts
Available for packaging	12,928		431		13,359
Packaged inventory	6,988		20		7,008
Packaging and supplies	20,709		—		20,709
	$	84,912	$	31,309	$	116,221


	SEPTEMBER 30, 2025
	CAPITALIZED COST		FAIR VALUE ADJUSTMENT		CARRYING VALUE
Plants in drying stage	$	4,794	$	2,928	$	7,722
Dry cannabis
Available for packaging	14,266		17,265		31,531
Packaged inventory	4,088		2,884		6,972
Flower and trim available for extraction	2,336		1,237		3,573
Concentrated extract	4,711		1,499		6,210
Formulated extracts
Available for packaging	20,267		668		20,935
Packaged inventory	11,414		346		11,760
Packaging and supplies	17,320		—		17,320
	$	79,196	$	26,827	$	106,023

Flower and trim available for extraction are converted into concentrated extract, which can then be used for oil formulation (combining with a carrier oil) or other products such as edibles, hash and vaporizable products.

The amount of inventory expensed in cost of sales for the three months ended December 31, 2025 was $34,215 (December 31, 2024 – $24,164). The amount of inventory provisions and waste for the three months ended December 31, 2025 was $1,750 (December 31, 2024 – $1,159), which include, provisions for excess and unsaleable inventories of $65 (December 31, 2024 – $13), adjustments to net realizable value of $273 (December 31, 2024 – $151), and processing and packaging waste of $1,412 (December 31, 2024 – $996), which is comprised of the production or purchase costs of these inventories.

The amount of realized fair value on inventories sold and other inventory charges for the three months ended December 31, 2025 was $16,911 (December 31, 2024 – $13,066), including realized fair value on inventories sold of $16,795 (December 31, 2024 – $12,519). Inventory provisions to recognize the realized fair value on waste and to adjust to net realizable value during the three months ended December 31, 2025 were $389 (December 31, 2024 – $698), consisting of $273 (December 31, 2024 – $151) recognized in cost of sales and $116 (December 31, 2024 – $547) recognized in fair value adjustments.

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED) | FOR THE THREE MONTHS ENDED DECEMBER 31, 2025 AND 2024 8

8. PROPERTY, PLANT AND EQUIPMENT


	LAND		BUILDINGS		GROWING & PROCESSING EQUIPMENT		LEASEHOLD IMPROVEMENTS		OTHER		RIGHT-OF-USE ASSETS		TOTAL
Cost





Balance, September 30, 2025	$	4,705	$	164,007	$	186,310	$	11,152	$	17,782	$	9,503	$	393,459

Additions	—		341		2,816		178		382		—		3,717



Balance, December 31, 2025	$	4,705	$	164,348	$	189,126	$	11,330	$	18,164	$	9,503	$	397,176

Accumulated depreciation and impairment





Balance, September 30, 2025	$	(2,721)	$	(109,222)	$	(143,350)	$	(1,327)	$	(12,268)	$	(1,594)	$	(270,482)
Depreciation	—		(788)		(1,763)		(160)		(196)		(305)		(3,212)




Balance, December 31, 2025	$	(2,721)	$	(110,010)	$	(145,113)	$	(1,487)	$	(12,464)	$	(1,899)	$	(273,694)

Net book value
September 30, 2025	$	1,984	$	54,785	$	42,960	$	9,825	$	5,514	$	7,909	$	122,977
December 31, 2025	$	1,984	$	54,338	$	44,013	$	9,843	$	5,700	$	7,604	$	123,482

Included in deferred charges and deposits is $2,069 (September 30, 2025 – $3,540) paid to secure the acquisition of growing and processing equipment. The amounts will be recorded in property, plant and equipment as equipment is received.

Reconciliation of property, plant, and equipment additions to the statements of cash flows

The following table reconciles additions of property, plant, and equipment per the above table to the purchases of property, plant, and equipment per the statements of cash flows:


	DECEMBER 31, 2025		DECEMBER 31, 2024
Total additions (including right-of-use lease assets)	$	3,717	$	26,417
Additions related to business combinations	—		(25,608)

Net change in deferred charges and deposits related to purchases of property, plant and equipment	(1,471)		675

Net change in accounts payable and accrued liabilities related to purchases of property, plant and equipment	(142)		142
Purchase of property, plant and equipment	$	2,104	$	1,626

9. OTHER FINANCIAL ASSETS

The following table outlines changes in other financial assets. Note 16 provides additional details on the fair value calculation of each investment.


ENTITY	ASSET TYPE	BALANCE, SEPTEMBER 30, 2025		FUNDED DURING THE QUARTER		FAIR VALUE CHANGES		BALANCE, DECEMBER 31, 2025
Weekend Holdings Corp. ("WHC")	Preferred shares	$	6,107	$	—	$	(419)	$	5,688
Phylos Bioscience Inc. ("Phylos")	Secured convertible loan	$	12,459	$	2,510	$	(2,888)	$	12,081
Steady State LLC (d/b/a Open Book Extracts) ("OBX")	Convertible loan	$	3,462	$	—	$	67	$	3,529
Sanity Group GmbH ("Sanity Group")	Convertible loan	$	23,552	$	—	$	700	$	24,252
Sanity Group	Common shares	$	3,968	$	—	$	(113)	$	3,855
		$	49,548	$	2,510	$	(2,653)	$	49,405

Phylos Bioscience Inc.

In December 2025, the secured convertible loan agreement (the “Secured Convertible Loan Agreement”) entered into on May 25, 2023 was amended to provide for additional advances of up to US$3.0 million, increasing the total aggregate principal amount available under the agreement to US$10.0 million. The amendment also revised certain milestone, maturity, conversion and warrant terms, and introduced provisions for the suspension of interest accrual commencing on May 24, 2028.

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED) | FOR THE THREE MONTHS ENDED DECEMBER 31, 2025 AND 2024 9

During the three months ended December 31, 2025, the Company advanced US$1,819 ($2,510) to Phylos in accordance with the amended Secured Convertible Loan Agreement.

10. DERIVATIVE LIABILITIES

The following table outlines changes in derivative liabilities, which are measured at fair value with changes recognized in the condensed consolidated interim statements of operations and comprehensive income (loss).


	DECEMBER 31, 2025				SEPTEMBER 30, 2025
	CURRENT		LONG-TERM		CURRENT		LONG-TERM
Top-up Rights	$	16,664	$	—	$	28,821	$	—
Secured Convertible Loan Agreement	41		—		11		—

Warrants	—		4,644		—		5,506
	$	16,705	$	4,644	$	28,832	$	5,506

i. Top-up Rights

As at December 31, 2025, the Company revalued the top-up rights (the "Top-up Rights") of BAT to an estimated fair value of $16,664 (September 30, 2025 – $28,821). The Company recorded a decrease in the estimated fair value change of the Top-up Rights for the three months ended December 31, 2025 of $12,157 (December 31, 2024 – increase of $18,945).

The following inputs were used to estimate the fair value of the Top-up Rights at December 31, 2025 and September 30, 2025:


	DECEMBER 31, 2025
	STOCK OPTIONS	WARRANTS	PSUs	RSUs	TOP-UP OPTIONS
Average exercise price	$1.20 - $45.08	$3.65	$—	$—	$1.90 - $12.07
Risk free interest rate	2.22% - 2.77%	2.63%	2.77%	2.75%	2.60%
Expected future volatility of Common Shares	60.00% - 70.00%	70.00%	70.00%	70.00%	40.00%
Expected life (years)	0.42 - 3.25	2.25	3.24	3.08	0.16
Forfeiture rate	10%	—%	25%	5%	—%


	SEPTEMBER 30, 2025
	STOCK OPTIONS	WARRANTS	PSUs	RSUs	TOP-UP OPTIONS
Average exercise price	$1.20 - $45.08	$2.50	$—	$—	$1.20 - $2.23
Risk free interest rate	2.44% - 2.57%	2.50%	2.48%	2.46%	3.10%
Expected future volatility of Common Shares	60.00% - 70.00%	70.00%	70.00%	70.00%	40.00%
Expected life (years)	1.42 - 3.26	2.42	2.10	1.75	0.34
Forfeiture rate	10%	—%	25%	5%	—%

ii. Warrants

During the three months ended December 31, 2025, no warrants were exercised. As at December 31, 2025, the Company revalued the derivative liability for warrants to an estimated fair value of $4,644 (September 30, 2025 – $5,506). The Company recorded a decrease in the estimated fair value of the derivative liabilities for the three months ended December 31, 2025 of $862 (December 31, 2024 – $3,348).

The following inputs were used to estimate the fair value of the warrants as at December 31, 2025:


	DECEMBER 31, 2025
Risk free interest rate	2.55		%
Life of Warrants (years)	2.25
Market price of Common Shares	$	2.31
Expected future volatility of Common Shares	99.30		%
Fair value per Warrant	$	1.04

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED) | FOR THE THREE MONTHS ENDED DECEMBER 31, 2025 AND 2024 10

11. OTHER CURRENT AND LONG-TERM LIABILITIES

The carrying value of other current and long-term liabilities as at December 31, 2025 and September 30, 2025 consists of:


	DECEMBER 31, 2025				SEPTEMBER 30, 2025
	CURRENT		LONG-TERM		CURRENT		LONG-TERM
Lease liabilities	$	937	$	7,505	$	979	$	7,748
Contingent consideration	5,320		$	—	6,719		5,015
Deferred consideration	—		$	—	357		—
Long-term debt	10		—		25		—
	$	6,267	$	7,505	$	8,080	$	12,763

12. PREFERRED SHARES

As at December 31, 2025, the Company revalued the Preferred Shares to an estimated fair value of $55,017 (September 30, 2025 – $68,653). For the three months ended December 31, 2025, the Company recognized a fair value gain of $13,637 (December 31, 2024 – loss of $3,735), in the condensed consolidated interim statements of operations and comprehensive income (loss).

13. SHARE CAPITAL

i. Issuances of share capital

Exercise of stock options

During the three months ended December 31, 2025, 3,350 (December 31, 2024 – $nil) share options were exercised at an average exercise price of $1.90 (December 31, 2024 - $nil) for an increase of $11 (December 31, 2024 - $nil) to share capital and a decrease to equity reserves of $5 (December 31, 2024 - $nil).

Exercise of restricted share units ("RSUs")

During the three months ended December 31, 2025, 579,918 (December 31, 2024 – $337,231) RSUs were exercised for an increase of $1,255 (December 31, 2024 – $653) to share capital and a decrease to equity reserves of $1,255 (December 31, 2024 – $653).

Exercise of performance share units ("PSUs")

During the three months ended December 31, 2025, 88,485 (December 31, 2024 – $nil) PSUs were exercised for an increase of $438 (December 31, 2024 – $nil) to share capital and a decrease to equity reserves of $438 (December 31, 2024 - $nil).

ii. Share-based compensation

During the three months ended December 31, 2025, the Company recognized total share-based compensation charges, including those related to production employees that are charged to biological assets and inventory, of $770 (December 31, 2024 – $1,325).

Stock options

The following table summarizes changes in the Company’s outstanding stock options for the three months ended December 31, 2025:


	NUMBER	WEIGHTED AVERAGE EXERCISE PRICE
Balance - September 30, 2025	2,301,674	$	10.03

Exercised	(3,350)	$	1.90

Expired	(66,979)	$	5.60
Balance - December 31, 2025	2,231,345	$	10.17

For the three months ended December 31, 2025, share-based compensation charges, including related to production employees that are charged to biological assets and inventory, were $nil (December 31, 2024 – $13) related to the Company’s stock option plan.

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED) | FOR THE THREE MONTHS ENDED DECEMBER 31, 2025 AND 2024 11

Equity incentive plan

The following table summarizes the movement in the Company’s outstanding RSUs:


			NUMBER
Balance - September 30, 2025			2,996,794
Granted			1,115,541
Exercised			(579,918)
Cancelled / Forfeited			(46,658)
Balance - December 31, 2025			3,485,759

The estimated fair value of the equity-settled RSUs granted during the three months ended December 31, 2025 was $2,426 (December 31, 2024 – $2,490), which was based on the Company’s share price at the grant date and will be recognized as an expense over the vesting period of the RSUs, which is over a period of three years for most grants.

For the three months ended December 31, 2025, $923 (December 31, 2024 – $1,071) has been recognized as share-based compensation expense.

The following table summarizes the movements in the Company’s outstanding PSUs:


			NUMBER
Balance - September 30, 2025			1,677,762
Granted			728,261
Exercised			(88,485)
Cancelled / Forfeited			(124,594)
Balance - December 31, 2025			2,192,944

The estimated fair value of the equity-settled PSUs granted during the three months ended December 31, 2025 was $1,066 (December 31, 2024 – $812), which was based on the Company’s share price at the grant date, adjusted for an estimate of the likelihood of forfeiture, and will be recognized as an expense over the vesting period of the PSUs, which is three years.

For the three months ended December 31, 2025, recovery of $153 (December 31, 2024 – expense of $241) has been recognized as share-based compensation expense.

14. RELATED PARTY TRANSACTIONS AND BALANCES

Management and Board Compensation

For the three months ended December 31, 2025 and December 31, 2024, the Company’s expenses included the following management and Board of Directors compensation:


	THREE MONTHS ENDED
		DECEMBER 31, 2025		DECEMBER 31, 2024
Salaries and bonus		$	1,377	$	1,302
Share-based compensation		476		775
Total key management compensation		$	1,853	$	2,077

Significant Transactions with Associates and Joint Operations

The Company has transactions with related parties, as defined in IAS 24 - Related Party Disclosures, all of which are undertaken in the normal course of business.

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED) | FOR THE THREE MONTHS ENDED DECEMBER 31, 2025 AND 2024 12

Company incurred $1,227 (December 31, 2024 – $1,474) of direct expenses and capital expenditures of $nil (December 31, 2024 – $nil) related to the Centre of Excellence. The Company recorded in the three months ended December 31, 2025, $951 (December 31, 2024 – $946) of these expenditures within research and development expense in the condensed consolidated interim statement of operations and comprehensive income (loss). For the three months ended December 31, 2025, the Company recorded $nil (December 31, 2024 – $nil) of capital expenditures which are included in the condensed consolidated interim statement of financial position.

At December 31, 2025, there is a balance receivable from BAT of $848 (September 30, 2025 – $701).

15. CAPITAL MANAGEMENT

The Company's capital consists of long-term debt (including current portion), derivative liabilities, preferred shares, share capital, equity reserves, accumulated other comprehensive loss, and accumulated deficit, which at December 31, 2025 is $445,832 (September 30, 2025 - $452,146). Equity reserves is comprised of any amounts recorded with respect to the recognition of share-based compensation expense (stock options, RSUs, or PSUs) and the fair value of warrants issued. Accumulated other comprehensive loss is entirely comprised of fair value changes recorded on the Company's investment in WHC.

The Company manages its capital structure and adjusts it based on funds available to the Company, in order to fund its growth. The Board of Directors does not establish quantitative return on capital criteria for management, but rather relies on the expertise of the Company’s management to sustain future development of the business.

Management reviews its capital management approach on an ongoing basis and believes that this approach, given the relative stage of the Company, is reasonable. There were no changes to the Company's approach to capital management during the period.

16. FAIR VALUE OF FINANCIAL INSTRUMENTS AND FINANCIAL RISK FACTORS

i.Fair value of financial instruments

The three levels of the fair value hierarchy are described as follows:

•level 1 inputs are quoted prices in active markets for identical assets or liabilities that the entity can access at the measurement date;

•level 2 inputs, other than quoted prices included within level 1, that are observable for the asset or liability, either directly or indirectly; and

•level 3 inputs are unobservable inputs for the asset or liability.

The fair values of cash, short term investments, accounts and other receivables, accounts payable and accrued liabilities and restricted funds approximate their carrying amounts due to their short-term nature.

The fair value of the investment in WHC is primarily based on level 3 unobservable inputs and is determined using a market-based approach, based on revenue multiples for comparable companies.

The fair value of the secured convertible loan advanced to Phylos under the Secured Convertible Loan Agreement, as amended, was determined using the Cox-Ross-Rubinstein binomial lattice option pricing model and has been classified as level 3 in the fair value hierarchy. The fair value of the secured convertible loan was based on certain assumptions, including likelihood, and timing of the federal legalization or decriminalization of cannabis in the United States. Similarly, the fair value of the commitment to fund an additional US $1 million was based on certain assumptions, including the probability of Phylos achieving required milestones.

The fair value of the convertible promissory note issued to OBX was determined using the binomial lattice model. The key assumptions used in the model are OBX stock price, dividend yield, expected future volatility of OBX stock, credit risk-adjusted discounting rate, risk-free rate, and probability and timing of certain qualified events. The credit risk-adjusted discounting rate and the expected equity volatility are based on unobservable inputs and are categorized as level 3 in the fair value hierarchy.

The fair value of the Top-up Rights is based on level 3 inputs utilized in a Monte Carlo pricing model to estimate the fair value of such Top-up Rights. The key assumptions used in the model are the expected future price of the Company’s Common Shares, the weighted average expected life of the instruments and the expected future volatility of Common Shares.

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED) | FOR THE THREE MONTHS ENDED DECEMBER 31, 2025 AND 2024 13

The fair value of the convertible note issued by Sanity Group to the Company was determined using the binomial lattice model. The key assumptions used in the Model are Sanity Group stock price, dividend yield, expected future volatility of Sanity Group stock, credit risk-adjusted discounting rate, risk-free rate, and probability and timing of certain qualified and non-qualified events. The credit risk-adjusted discounting rate and the expected equity volatility are based on unobservable inputs and are categorized as level 3 in the fair value hierarchy.

The fair value of the Company's equity interest in the Sanity Group was determined using the option pricing model wherein the current value of the Sanity Group was allocated to the various types of shares based on their rights and preferences. The current value of the Sanity Group was determined using the backsolve approach which benchmarks the original issue price of the Sanity Group's latest funding transaction.

The fair value of derivative warrant liabilities is based on level 1 and 2 inputs utilized in a Black-Scholes option pricing model to estimate the fair value of such warrants. The key assumption used in the model is the expected future volatility in the price of the Company’s Common Shares. If the expected future volatility in the common share price of the Company increased by 10%, the estimated fair value of the derivative warrant liability and net loss would increase by $536 or if it decreased by 10%, the estimated fair value of the derivative warrant liability and net loss would decrease by $562.

The fair value of the additional contingent share consideration payable to Motif's former shareholders in connection with the Company's acquisition of Motif in December 2024 is primarily based on level 3 unobservable inputs in a Monte Carlo pricing model. The model simulates daily share price of the Company for twelve months and monitors when the share achieves a volume weighted average trading price, which would trigger the issuance of the contingent share consideration. The key assumptions used in the model are expected future price and the expected future volatility of the Company's Common Shares.

The fair value of the additional contingent consideration payable to CPL's former shareholders in connection with the Company's acquisition of CPL in March 2025 is primarily based on level 3 unobservable inputs in a Monte Carlo pricing model. The determination of the fair value of this liability is primarily driven by the Company’s expectations of CPL achieving its milestones. The key inputs used in the model are revenue, discount rate, revenue and asset volatility and risk free rate.

The fair value of Preferred Shares is based on level 1, level 2 and level 3 inputs and is determined based on market price and volatility of the Company's Common Shares, risk free rate and discount for lack of marketability.

During the period, there were no transfers of amounts between levels 1, 2 and 3.

For the three months ended December 31, 2025, and December 31, 2024, the Company recorded the following fair value changes related to its financial instruments:


	THREE MONTHS ENDED
	DECEMBER 31, 2025		DECEMBER 31, 2024
Investment in Phylos	$	2,888	$	(2,471)
Investment in OBX	(67)		(288)
Investment in Sanity Group (convertible loan)	(700)		(1,151)
Investment in Sanity Group (common shares)	113		47
Top-up Rights	(12,157)		18,945
Commitment to fund third tranche of Phylos convertible loan	30		(303)
Commitment to issue Preferred Shares	—		(671)
Warrants	(862)		(3,348)
Preferred shares	(13,637)		3,735
	$	(24,392)	$	14,495

Additionally, for the three months ended December 31, 2025, and December 31, 2024, the Company also fair valued its investment in WHC and recognized a decrease in fair value of $419 (December 31, 2024 – increase of $240) in the consolidated statements of operations and comprehensive income (loss) within other comprehensive income (loss).

ii.Financial risk factors

The Company is exposed to various risks through its financial instruments, as follows:

(a) Credit risk arises from deposits with banks, short-term investments, outstanding trade and other receivables, restricted funds and other financial assets. For trade receivables, the Company does not hold any collateral as security but mitigates this risk by dealing only with what management believes to be financially sound counterparties and, accordingly, does not anticipate significant loss for non-performance, except potentially from outstanding receivable from one of the international customers. For certain trade and other receivables, management also obtains insurance, guarantees or general security

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED) | FOR THE THREE MONTHS ENDED DECEMBER 31, 2025 AND 2024 14

agreements, where applicable. The maximum exposure to credit risk of cash, restricted cash, short-term investments, accounts and other receivables and other financial assets on the statement of financial position at December 31, 2025 approximates $162,312 (September 30, 2025 – $198,827).

As of December 31, 2025 and September 30, 2025, the Company’s aging of trade receivables was as follows:


	DECEMBER 31, 2025		SEPTEMBER 30, 2025
0-90 days	$	38,568	$	56,442
More than 90 days	15,622		12,846
Gross trade receivables	$	54,190	$	69,288
Less: Expected credit losses and reserve for product returns and price adjustments	(5,118)		(5,703)
	$	49,072	$	63,585

(b) Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they come due. The Company manages its liquidity risk by reviewing its capital requirements and liquidity position on an ongoing basis. At December 31, 2025, the Company had $7,576 (September 30, 2025 – $28,200) of cash (unrestricted) and working capital of $162,494 (September 30, 2025 – $158,738). If necessary, the Company may access additional liquidity through the capital markets, including both debt and equity financing.

The Company is obligated to the following contractual maturities relating to their undiscounted cash flows as at December 31, 2025:


	Carrying Amount		Contractual Cash Flows		Less than 1 year		1 to 3 years		3 to 5 years		More than 5 years
Accounts payable and accrued liabilities	71,079		71,079		71,079		—		—		—
Long-term debt	10		10		10		—		—		—
Lease obligations	8,442		10,862		1,529		3,178		2,878		3,277
	$	79,531	$	81,951	$	72,618	$	3,178	$	2,878	$	3,277

The contractual maturities noted above are based on contractual due dates of the respective financial liabilities.

In connection with the Company’s facilities, the Company is contractually committed to approximately $925 of capital expenditures.

(c) Market risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices. Market risk for the Company is comprised of interest rate risk. Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company’s exposure to the risk of changes in market interest rates relates primarily to the Company’s debt obligations with floating interest rates. The Company has determined that a 1% change in rates would not have a material impact on the interim financial statements.

17. REVENUE

Net revenue for the Company is defined as gross revenue, which is net of any customer discounts, rebates, and sales returns and recoveries, less excise taxes.

Gross revenue for the three months ended December 31, 2025 and December 31, 2024 is disaggregated as follows:


	THREE MONTHS ENDED
	DECEMBER 31, 2025		DECEMBER 31, 2024
Recreational revenue (Canadian)	$	87,831	$	62,634
Wholesale to licensed producers (Canadian)	3,592		346
International wholesale	5,042		3,330
Direct to patient medical and medical wholesale revenue (Canadian)	758		496

Other revenue	75		—
Gross revenue	$	97,298	$	66,806
Excise taxes	(33,760)		(24,076)
Net revenue	$	63,538	$	42,730

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED) | FOR THE THREE MONTHS ENDED DECEMBER 31, 2025 AND 2024 15

Recreational revenue is primarily generated from sales to provincial government distributors and large retailers that sell cannabis through their respective distribution networks. International and domestic wholesale revenue consists of bulk shipments to other cannabis companies, including Licensed Producers, for further processing and resale to end customers.

During the three months ended December 31, 2025, the Company had four customers (December 31, 2024 – three customers), that individually represented more than 10% of the Company’s net revenue.

18. GENERAL AND ADMINISTRATIVE EXPENSES BY NATURE


	THREE MONTHS ENDED
	DECEMBER 31, 2025		DECEMBER 31, 2024
Office and general	$	4,660	$	3,441
Wages and benefits	5,007		4,988
Professional fees	2,678		1,476
Depreciation and amortization	2,215		1,057
Travel and accommodation	156		154
Utilities	234		117
Total general and administrative expenses	$	14,950	$	11,233

19. OPERATING SEGMENTS

An operating segment is a component of the Company for which discrete financial information is available and whose operating results are regularly reviewed by the Company's chief operating decision maker, to make decisions about resources to be allocated to the segment and assess its performance, and that engages in business activities from which it may earn revenue and incur expenses. The Company has one operating segment.

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED) | FOR THE THREE MONTHS ENDED DECEMBER 31, 2025 AND 2024 16

Form 52-109F2

Certification of Interim Filings

Full Certificate

I, James Yamanaka, Chief Executive Officer of Organigram Global Inc., certify the following:

1. Review: I have reviewed the interim financial report and interim MD&A (together, the "interim filings") of Organigram Global Inc. (the "issuer") for the interim period ended December 31, 2025.

2. No misrepresentations: Based on my knowledge, having exercised reasonable diligence, the interim filings do not contain any untrue statement of a material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it was made, with respect to the period covered by the interim filings.

3. Fair presentation: Based on my knowledge, having exercised reasonable diligence, the interim financial report together with the other financial information included in the interim filings fairly present in all material respects the financial condition, financial performance and cash flows of the issuer, as of the date of and for the periods presented in the interim filings.

4. Responsibility: The issuer's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (DC&P) and internal control over financial reporting (ICFR), as those terms are defined in National Instrument 52-109 Certification of Disclosure in Issuers' Annual and Interim Filings, for the issuer.

5. Design: Subject to the limitations, if any, described in paragraphs 5.2 and 5.3, the issuer's other certifying officer(s) and I have, as at the end of the period covered by the interim filings

(a) designed DC&P, or caused it to be designed under our supervision, to provide reasonable assurance that

(i) material information relating to the issuer is made known to us by others, particularly during the period in which the interim filings are being prepared; and

(ii) information required to be disclosed by the issuer in its annual filings, interim filings or other reports filed or submitted by it under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation; and

(b) designed ICFR, or caused it to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuer's GAAP.

5.1 Control framework: The control framework the issuer's other certifying officer(s) and I used to design the issuer's ICFR is the Internal Control - Integrated Framework (COSO Framework 2013) published by The Committee of Sponsoring Organizations of the Treadway Commission (COSO).

5.2 ICFR - material weakness relating to design: The issuer has disclosed in its interim MD&A for each material weakness relating to design existing at the end of the interim period

(a) a description of the material weakness;

(b) the impact of the material weakness on the issuer's financial reporting and its ICFR; and

1.3Limitation on scope of design: The issuer has described in its interim MD&A

(a)the fact that the issuer’s other certifying officer(s) and I have limited the scope of our design of DC&P and ICFR to exclude controls, policies and procedures of

(i)N/A

(ii)N/A

(iii)a business that the issuer acquired not more than 365 days before the last day covered by the period of the interim filings; and

(b)summary financial information about the proportionately consolidated entity, special purpose entity or business that the issuer acquired that has been proportionately consolidated or consolidated in the issuer’s financial statements.

6. Reporting changes in ICFR: The issuer has disclosed in its interim MD&A any change in the issuer's ICFR that occurred during the period beginning on October 1, 2025 and ended on December 31, 2025 that has materially affected, or is reasonably likely to materially affect, the issuer's ICFR.

Date: February 10, 2026

(signed) “James Yamanaka”

James Yamanaka

Chief Executive Officer

Form 52-109F2

Certification of Interim Filings

Full Certificate

I, Greg Guyatt, Chief Financial Officer of Organigram Global Inc., certify the following:

1. Review: I have reviewed the interim financial report and interim MD&A (together, the "interim filings") of Organigram Global Inc. (the "issuer") for the interim period ended December 31, 2025.

5. Design: Subject to the limitations, if any, described in paragraphs 5.2 and 5.3, the issuer's other certifying officer(s) and I have, as at the end of the period covered by the interim filings

(a) designed DC&P, or caused it to be designed under our supervision, to provide reasonable assurance that

(i) material information relating to the issuer is made known to us by others, particularly during the period in which the interim filings are being prepared; and

5.2 ICFR - material weakness relating to design: The issuer has disclosed in its interim MD&A for each material weakness relating to design existing at the end of the interim period

(a) a description of the material weakness;

(b) the impact of the material weakness on the issuer's financial reporting and its ICFR; and

1.3Limitation on scope of design: The issuer has described in its interim MD&A

(a)the fact that the issuer’s other certifying officer(s) and I have limited the scope of our design of DC&P and ICFR to exclude controls, policies and procedures of

(i)N/A

(ii)N/A

(iii)a business that the issuer acquired not more than 365 days before the last day covered by the period of the interim filings; and

Date: February 10, 2026

(signed) “Greg Guyatt”

Greg Guyatt

Chief Financial Officer

Organigram Reports First Quarter Fiscal 2026 Results

Strong year-over-year growth supported by Canadian leadership and growing international sales, improving gross margin.

TORONTO, ON, February 10, 2026 - Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), Canada's #1 cannabis company by market share1, is pleased to announce its results for the first quarter ended December 31, 2025 (“Q1 Fiscal 2026” or "Q1").

Q1 FISCAL 2026 HIGHLIGHTS

•Gross Revenue: $97.3 million (+46% year-over-year).

•Net Revenue: $63.5 million (+49% year-over-year).

•International Revenue: $5.0 million (+51% year-over-year).

•Adjusted EBITDA2: $5.3 million (+273% year-over-year).

•#1 Market Share in Canada: #1 in vapes, #1 in milled flower, #1 in concentrates, #2 in pre-rolls #3 in edibles, #3 in dried flower1.

•U.S. Expansion: Launched Collective Project & Fetch into Illinois and Wisconsin through new distribution partners, expanding US retail footprint to 11 states3.

•Powdery Mildew Resistance: Achieved proprietary genetic screening breakthrough that shortens powdery mildew resistance identification from months to days across a wide range of cultivars, enabling earlier selection and avoiding investment in non-resistant plants. Resistance is being bred into commercial cultivars to improve yield stability while reducing crop loss and production costs.

•Yield Improvement: Kilograms harvested increased 43% to 28,645 compared to Q1 Fiscal 2025. The yield increases were achieved through nutrient and environmental enhancements, which contributed to lower per unit costs.

“As I step into the role of CEO, I’m encouraged by the strength of Organigram and our leadership position in Canada,” said James Yamanaka, CEO of Organigram. “Over the past 25 days, I’ve toured our facilities and met with many of my new colleagues. What’s clear is that we have a competitive core business, supported by a foundation of innovation and plant science, alongside a continued focus on improving efficiency and scale. As our international presence grows, disciplined execution and operating efficiency will drive profitability.”

FIRST QUARTER FISCAL 2026 FINANCIAL OVERVIEW

•Net revenue:

1 Multiple Sources (Hifyre, Weedcrawler, provincial boards, internal modelling) as of December, 2025.

2 Adjusted gross margin, adjusted gross margin %, and adjusted EBITDA are non-IFRS financial measures not defined by and do not have any standardized meanings under IFRS, as issued by the International Accounting Standards Board, and might not be comparable to similar financial measures disclosed by other issuers; please refer to "Non-IFRS Financial Measures" in this press release for more information.

3 In November 2025, the U.S. enacted the Continuing Appropriations and Extensions Act of 2026 (H.R. 5371), which includes a provision (section 781) to amend the definition of hemp in the 2018 Farm Bill to effectively eliminate hemp-derived THC products, although the change does not become effective for 365 days from the date of enactment. Organigram’s U.S. offerings would be directly impacted by this change in law; additionally, Organigram has investments in hemp seed and hemp ingredient manufacturers in the U.S. that may be impacted by this legislation. Efforts are underway to repeal, replace, or delay this amendment, but whether any change will occur is uncertain. If current federal legislation is not amended or reversed, Organigram may have to sell, wind-down or otherwise restructure its hemp THC product related activities in the U.S. by November 2026.

◦Net Revenue increased 49% to $63.5 million, from $42.7 million in the first quarter ended December 31, 2024 ("Q1 Fiscal 2025"), primarily driven by contributions from the Motif Labs Ltd. ("Motif") acquisition and increased international sales.

•Adjusted gross margin4:

◦Adjusted Gross Margin was $23.9 million, or 38% of net revenue, compared to $14.3 million, or 33%, in Q1 Fiscal 2025. The increase in adjusted gross margin was driven by the realization of investments in operational efficiencies, higher flower yields, synergies gained from the integration of Motif, and higher international sales.

•Selling, General & Administrative ("SG&A") Expenses:

◦SG&A increased to $23.9 million from $17.0 million in Q1 Fiscal 2025. The increase was attributable to the inclusion of Motif SG&A in Organigram's consolidated financials as well as higher trade investments to support the growth of the business.

◦As a proportion of net revenue, SG&A declined to 38%, compared to 40% in Q1 Fiscal 2025.

•Net Income:

◦Net income was $20.0 million compared to net loss of $27.5 million in Q1 Fiscal 2025. The increase in net income from the prior period is primarily attributable to higher fair value changes recognized in relation to the preferred shares and top-up-rights held by British American Tobacco p.l.c ("BAT"), and other financial instruments.

•Adjusted EBITDA4:

◦Adjusted EBITDA was $5.3 million compared to $1.4 million in adjusted EBITDA in Q1 Fiscal 2025. The increase was primarily attributable to higher recreational revenue, including Motif contributions, and higher international revenue, and higher adjusted gross margin.

•Net Cash (used in) provided by Operating Activities:

◦Cash (used in) provided by operating activities before working capital changes was $0.3 million, compared to $(6.3) million in Q1 Fiscal 2025. The improvement in cash (used in) provided by operating activities before working capital changes was driven by the improvement in adjusted EBITDA4.

◦Cash (used in) provided by operating activities was $(16.0) million, compared to cash used of $(4.2) million in Q1 Fiscal 2025. The increase was primarily attributable to higher investment in working capital.

“Year over year, we delivered strong revenue growth and improved profitability, reflecting the scale we’ve built across the business,” said Greg Guyatt, CFO of Organigram. “Despite expected seasonal and market dynamics early in the year, adjusted gross margin remained elevated due to greater operational efficiency, higher flower yields, synergies gained from the integration of Motif, and higher international sales. We expect this trend to continue throughout Fiscal 2026, where we project further international sales growth."

INTERNATIONAL SALES

4 Adjusted gross margin, adjusted gross margin %, and adjusted EBITDA are non-IFRS financial measures not defined by and do not have any standardized meanings under IFRS, as issued by the International Accounting Standards Board, and might not be comparable to similar financial measures disclosed by other issuers; please refer to "Non-IFRS Financial Measures" in this press release for more information.

•In Q1 Fiscal 2026, Organigram achieved $5.0 million in international sales compared to $3.3 million in the same prior year period, and expects to continue growing its international sales over time.

•Organigram continues to await EU-GMP certification for its Moncton facility. The Company is preparing follow-up responses and information for the regulator in response to feedback received in January 2026. Following provision of this information, the Company expects to await confirmation of certification or any required next steps.

BALANCE SHEET & LIQUIDITY

•As of December 31, 2025, the Company had total cash (including restricted cash and short-term investments) of $63.0 million.


Select Key Financial Metrics (in $000s unless otherwise indicated)	Q1-2026		Q1-2025		% Change
Gross revenue	97,298		66,806		46	%
Excise taxes	(33,760)		(24,076)		40	%
Net revenue	63,538		42,730		49	%
Cost of sales	40,021		28,615		40	%
Gross margin before fair value changes to biological assets & inventories sold	23,517		14,115		67	%
Realized fair value on inventories sold and other inventory charges	(16,911)		(13,066)		29	%
Unrealized gain on changes in fair value of biological assets	16,709		12,765		31	%
Gross margin	23,315		13,814		69	%
Adjusted gross margin(1)	23,855		14,279		67	%
Adjusted gross margin %(1)	38	%	33	%	5	%
Selling (including marketing), general & administrative expenses	23,941		17,037		41	%
Net income (loss)	19,969		(27,461)		nm
Adjusted EBITDA(1)	5,265		1,410		273	%
Net cash provided by (used in) operating activities before working capital changes	253		(6,288)		nm
Net cash used in operating activities after working capital changes	(16,013)		(4,180)		283	%

Note (1) Adjusted gross margin, adjusted gross margin % and adjusted EBITDA are non-IFRS financial measures not defined by and do not have any standardized meaning under IFRS and might not be comparable to similar financial measures disclosed by other issuers; please refer to “Non-IFRS Financial Measures” in this press release for more information.


Select Balance Sheet Metrics (in $000s)	DECEMBER 31, 2025	SEPTEMBER 30, 2025	% Change
Cash & short-term investments (including restricted cash)	62,966	84,420	(25)	%
Biological assets & inventories	132,711	123,954	7	%
Other current assets	60,868	76,523	(20)	%
Accounts payable & accrued liabilities	71,079	89,247	(20)	%

Working capital	162,494	158,738	2	%
Property, plant & equipment	123,482	122,977	nm

Total assets	530,673	562,211	(6)	%
Total liabilities	161,217	213,081	(24)	%
Shareholders’ equity	369,456	349,130	6	%

The following table reconciles the Company's adjusted EBITDA to net income (loss).


Adjusted EBITDA Reconciliation (in $000s unless otherwise indicated)	Q1-2026		Q1-2025
Net income (loss) as reported	$	19,969	$	(22,957)
Add/(deduct):
Investment income, net of financing costs	(93)		(825)

Depreciation and amortization	4,980		3,387


ERP implementation costs	407		744
Acquisition and transaction costs	1,606		4,504
Inventory and biological assets fair value and NRV adjustments	540		465

Share-based compensation	770		1,325
Other (income) expenses(1)	(24,900)		12,477
Research and development expenditures, net of depreciation	1,986		2,290
Adjusted EBITDA	$	5,265	$	1,410

Note 1: Other (income) expenses includes share of loss from investments in associates, (gain) loss on disposal of property, plant and equipment, change in fair value of derivative liabilities, preferred shares, contingent consideration and other financial assets, and certain other non-operating (income) expenses.

RECONCILIATION

The following table reconciles the Company's adjusted gross margin to gross margin before fair value changes to biological assets and inventories sold:


Adjusted Gross Margin Reconciliation (in $000s unless otherwise indicated)	Q1-2026			Q1-2025
Net revenue	$	63,538		$	42,730
Cost of sales before adjustments	39,683			28,451
Adjusted gross margin	23,855			14,279
Adjusted gross margin %	38		%	33		%
Less:
Provisions and impairment of inventories and biological assets	65			13
Provisions to net realizable value	273			151



Gross margin before fair value adjustments	23,517			14,115
Gross margin % (before fair value adjustments)	37		%	33		%
Add:
Realized fair value on inventories sold and other inventory charges	(16,911)			(13,066)
Unrealized gain on changes in fair value of biological assets	16,709			12,765
Gross margin	23,315			13,814
Gross margin %	37		%	32		%

The following table reconciles the Company's Free Cash Flow to net cash and restricted cash provided by (used in) operating activities:


Free Cash Flow Reconciliation (in $000s unless otherwise indicated)	Q1-2026		Q1-2025
Net cash and restricted cash provided by (used in) operating activities	$	(16,013)	$	(4,180)
Less:
Purchase of property, plant and equipment	(2,104)		(1,626)
Free Cash Flow	(18,117)		(5,806)

First Quarter Fiscal 2026 Conference Call

The Company will host a conference call to discuss its results with details as follows:

Date: February 10, 2026

Time: 8:00 am Eastern Time

To register for the conference call, please use this link:

https://events.q4inc.com/analyst/430252525?pwd=WEt2KbHS

To ensure you are connected for the full call, we suggest registering a day in advance or at minimum 10 minutes before the start of the call. After registering, a confirmation will be sent through email, including dial in details and unique conference call codes for entry. Registration is open through the live call.

To access the webcast:

https://events.q4inc.com/attendee/430252525

A replay of the webcast will be available within 24 hours after the conclusion of the call at https://www.organigram.ca/investors and will be archived for a period of 90 days following the call.

Non-IFRS Financial Measures

This news release refers to certain financial performance measures (including adjusted gross margin, adjusted gross margin % and adjusted EBITDA) that are not defined by and do not have a standardized meaning under IFRS as issued by the International Accounting Standards Board. Non-IFRS financial measures are used by management to assess the financial and operational performance of the Company. The Company believes that these non-IFRS financial measures, in addition to conventional measures prepared in accordance with IFRS, enable investors to evaluate the Company’s operating results, underlying performance and prospects in a similar manner to the Company’s management. As there are no standardized methods of calculating these non-IFRS measures, the Company’s approaches may differ from those used by others, and accordingly, the use of these measures may not be directly comparable. Accordingly, these non-IFRS measures are intended to provide additional information and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with IFRS. Adjusted EBITDA is a non-IFRS measure that the Company defines as net income (loss) before: financing costs, net of investment income; income tax expense (recovery); depreciation, amortization, impairment, normalization of depreciation add-back due to changes in depreciable assets resulting from impairment charges, (gain) loss on disposal of property, plant and equipment (per the consolidated statement of cash flows); share-based compensation (per the consolidated statement of cash flows); share of loss (gain) from investments in associates including impairment loss; change in fair value of contingent consideration; change in fair value of derivative liabilities, other financial assets and preferred shares; expenditures incurred in connection with research and development activities (net of depreciation); unrealized gain on changes in fair value of biological assets; realized fair value on inventories sold and other inventory charges; provisions and net realizable value adjustments related to inventory and biological assets; government subsidies, insurance recoveries and other non-operating expenses (income); legal provisions (recoveries); ERP implementation costs; transaction costs; share issuance costs; and provision for Canndoc (as defined herein) expected credit losses. Adjusted EBITDA is intended to provide a proxy for the Company’s operating cash flow and derive expectations of future financial performance for the Company, and excludes adjustments that are not reflective of current operating results.

Adjusted gross margin is a non-IFRS measure that the Company defines as net revenue less cost of sales, before the effects of (i) unrealized gain on changes in fair value of biological assets; (ii) realized

fair value on inventories sold and other inventory charges; (iii) provisions and impairment of inventories and biological assets; and (iv) provisions to net realizable value. Adjusted gross margin % is calculated by dividing adjusted gross margin by net revenue. Management believes that these measures provide useful information to assess the profitability of our operations as they represent the normalized gross margin generated from operations and exclude the effects of non-cash fair value adjustments on inventories and biological assets, which are required by IFRS.

The most directly comparable measure to adjusted EBITDA, calculated in accordance with IFRS is net income (loss) and beginning on page 5 of this press release is a reconciliation to such measure. The most directly comparable measure to adjusted gross margin calculated in accordance with IFRS is gross margin before fair value changes to biological assets and inventories sold and beginning on page 5 of this press release is a reconciliation to such measure. The most directly comparable measure to Free Cash Flow is net cash and restricted cash provided by (used in) operating activities, and beginning on page 5 of this press release is a reconciliation to such measure.

About Organigram Global Inc.

Organigram Global Inc. is a NASDAQ Global Select Market and TSX listed company whose wholly-owned subsidiaries include Organigram Inc., a licensed cultivator or cannabis and manufacturer of cannabis-derived goods in Canada. Through its acquisition of Collective Project, Organigram Global participates in the U.S. and Canadian cannabinoid beverages markets.

Organigram is focused on producing high-quality, indoor-grown cannabis for patients and adult recreational consumers in Canada, as well as developing international business partnerships to extend the Company’s global footprint. Organigram has also developed a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O’ Buds, SHRED, SHRED'ems, Monjour, Tremblant Cannabis, Trailblazer, Collective Project, BOXHOT and DEBUNK. Organigram operates facilities in Moncton, New Brunswick and Lac-Supérieur, Québec, with a dedicated manufacturing facility in Winnipeg, Manitoba. The Company also operates two additional cannabis processing facilities in Southwestern Ontario; one in Aylmer and the other in London. The facility in Aylmer houses best-in-class CO2 and Hydrocarbon extraction capabilities, and is optimized for formulation refinement, post-processing of minor cannabinoids, and pre-roll production. The facility in London will be optimized for labelling, packaging, and national fulfillment. The Company is regulated by the Cannabis Act and the Cannabis Regulations (Canada).

Forward-Looking Information

This news release contains forward-looking information. Forward-looking information, in general, can be identified by the use of forward-looking terminology such as “outlook”, “objective”, “may”, “will”, “could”, “would”, “might”, “expect”, “intend”, “estimate”, “anticipate”, “believe”, “plan”, “continue”, “budget”, “schedule” or “forecast” or similar expressions suggesting future outcomes or events. They include, but are not limited to, statements with respect to expectations, projections or other characterizations of future events or circumstances, and the Company’s objectives, goals, strategies, beliefs, intentions, plans, estimates, forecasts, projections and outlook, including statements relating to the Company’s future performance, the Company’s positioning to capture additional market share and sales including international sales, expectations for consumer demand, expected improvement to gross margins before fair value changes to biological assets and inventories, expectations regarding adjusted gross margins, adjusted EBITDA, Free Cash Flow and net revenue in Fiscal 2026 and beyond, expectations regarding cultivation capacity, the Company’s plans and objectives including around the PDC, availability and sources of any future financing, availability of cost efficiency opportunities, the ability of the Company to fulfill demand for its revitalized product portfolio with increased staffing, expectations relating to greater capacity to meet demand due to increased capacity at the Company’s facilities, expectations around lower product

cultivation costs, the ability to achieve economies of scale and ramp up cultivation, expectations pertaining to the increase of automation and reduction in reliance on manual labour, expectations around the launch of higher margin dried flower strains, expectations around market and consumer demand and other patterns related to existing, new and planned product forms; expectations regarding the Company's acquisition, integration and synergy realization of Motif and Collective Project; expectations around FASTTM nanoemulsion technology; expectations regarding EU-GMP certification; timing for launch of new product forms, ability of those new product forms to capture sales and market share, estimates around incremental sales and more generally estimates or predictions of actions of customers, suppliers, partners, distributors, competitors or regulatory authorities; statements regarding the future of the Canadian and international cannabis markets and, statements regarding the Company’s future economic performance. These statements are not historical facts but instead represent management beliefs regarding future events, many of which, by their nature are inherently uncertain and beyond management control. Forward-looking information has been based on the Company’s current expectations about future events.

Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectations. These risks, uncertainties and factors include: general economic factors; international trade disputes sparked by tariffs and retaliatory tariffs or other non-tariff measures; changes to government laws, regulations or policies, including customs, tariffs, trade or environmental law, regulations or policies, or the enforcement thereof; receipt of regulatory approvals or consents and any conditions imposed upon same and the timing thereof; the Company's ability to meet regulatory criteria which may be subject to change; change in regulation including restrictions on sale of new product forms; change in stock exchange listing practices; the Company's ability to manage costs, timing and conditions to receiving any required testing results and certifications; results of final testing of new products; changes in governmental plans including those related to methods of distribution; timing and nature of sales and product returns; customer buying patterns and consumer preferences not being as predicted given this is a new and emerging market; material weaknesses identified in the Company’s internal controls over financial reporting; the completion of regulatory processes and registrations including for new products and forms; market demand and acceptance of new products and forms; unforeseen construction or delivery delays including of equipment and commissioning; increases to expected costs; competitive and industry conditions; change in customer buying patterns; and changes in crop yields. These and other risk factors are disclosed in the Company's documents filed from time to time under the Company’s issuer profile on the Canadian Securities Administrators’ System for Electronic Document Analysis and Retrieval+ (“SEDAR”) at www.sedarplus.ca and reports and other information filed with or furnished to the United States Securities and Exchange Commission (“SEC”) from time to time on the SEC’s Electronic Document Gathering and Retrieval System (“EDGAR”) at www.sec.gov, including the Company’s most recent management discussion and analysis ("MD&A") and annual information form. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this news release. The Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Forward looking information is subject to risks and uncertainties that are addressed in the “Risk Factors” section of the MD&A dated February 10, 2026 and there can be no assurance whatsoever that these events will occur.

This news release contains information concerning our industry and the markets in which we operate, including our market position and market share, which is based on information from independent third-party sources. Although we believe these sources to be generally reliable, market and industry data is inherently imprecise, subject to interpretation and cannot be verified with complete certainty due to limits on the availability and reliability of raw data, the voluntary nature of the data gathering process, and other limitations and uncertainties inherent in any statistical survey

or data collection process. We have not independently verified any third-party information contained herein.

For Investor Relations enquiries, please contact:

Max Schwartz, Director of Investor Relations

investors@organigram.ca

For Media enquiries, please contact:

Megan McCrae, Senior Vice President, Global Brands and Corporate Affairs

megan.mccrae@organigram.ca

Source: View Original Filing on SEC EDGAR

FAQ

How did Organigram (OGI) perform financially in Q1 Fiscal 2026?

Organigram posted strong year-over-year growth in Q1 Fiscal 2026, with net revenue reaching $63,538 versus $42,730. Gross margin before fair value adjustments rose to 37%, adjusted gross margin reached 38%, and net income was $19,969, reversing the prior-year loss.

What drove Organigram’s revenue growth in the quarter ended December 31, 2025?

Revenue growth was mainly driven by higher Canadian recreational cannabis sales and increased international and wholesale revenue. Recreational net revenue rose to $54,071, while international flower, beverages and other categories contributed $9,467, supported by the Motif acquisition’s sales contribution during the period.

What margins and profitability metrics did Organigram (OGI) report for Q1 Fiscal 2026?

Gross margin before fair value adjustments was $23,517, a 37% margin, and adjusted gross margin was $23,855, or 38%. Adjusted EBITDA reached $5,265, an 8% margin, while net income totaled $19,969, reflecting both operational improvements and fair value gains.

What guidance did Organigram provide for Fiscal 2026 revenue and cash flow?

Organigram expects Fiscal 2026 net revenue to exceed $300 million, with adjusted gross margin above Fiscal 2025 levels. Management also anticipates adjusted EBITDA higher than Fiscal 2025 and positive free cash flow, while keeping capital expenditures below $10,000 during the fiscal year.

What is Organigram’s liquidity position as of December 31, 2025?

As of December 31, 2025, Organigram had $62,966 in cash, restricted cash and short-term investments and working capital of $162,494. The company used $16,013 in operating cash and reported free cash flow of negative $18,117 for the quarter.

What internal control issues did Organigram disclose for Q1 Fiscal 2026?

Management concluded that internal control over financial reporting was not effective as of December 31, 2025, due to a remaining material weakness involving complex spreadsheets and related processes. Remediation efforts are underway, with completion targeted before the end of Fiscal 2026.

How could U.S. regulatory changes affect Organigram’s hemp-derived THC business?

A U.S. law amending the hemp definition could effectively eliminate hemp-derived THC products after a 365-day period. Organigram may need to sell, wind-down or restructure its U.S. hemp THC activities by November 2026 if the legislation is not repealed, replaced or delayed.

Filing Exhibits & Attachments

5 documents

Organigram (OGI) swings to profit as Q1 2026 revenue jumps and margins improve

Rhea-AI Filing Summary

Positive

Negative

Insights

FAQ

How did Organigram (OGI) perform financially in Q1 Fiscal 2026?

What drove Organigram’s revenue growth in the quarter ended December 31, 2025?

What margins and profitability metrics did Organigram (OGI) report for Q1 Fiscal 2026?

What guidance did Organigram provide for Fiscal 2026 revenue and cash flow?

What is Organigram’s liquidity position as of December 31, 2025?

What internal control issues did Organigram disclose for Q1 Fiscal 2026?

How could U.S. regulatory changes affect Organigram’s hemp-derived THC business?

Filing Exhibits & Attachments

Press Releases

NASDAQ:OGI

OGI Rankings

OGI Latest News

OGI Latest SEC Filings

OGI Stock Data

Trending News

Organigram (OGI) swings to profit as Q1 2026 revenue jumps and margins improve

Rhea-AI Filing Summary

Positive

Negative

Insights

Equity research analyst positive

FAQ

How did Organigram (OGI) perform financially in Q1 Fiscal 2026?

What drove Organigram’s revenue growth in the quarter ended December 31, 2025?

What margins and profitability metrics did Organigram (OGI) report for Q1 Fiscal 2026?

What guidance did Organigram provide for Fiscal 2026 revenue and cash flow?

What is Organigram’s liquidity position as of December 31, 2025?

What internal control issues did Organigram disclose for Q1 Fiscal 2026?

How could U.S. regulatory changes affect Organigram’s hemp-derived THC business?

Filing Exhibits & Attachments

Press Releases

NASDAQ:OGI

OGI Rankings

OGI Latest News

OGI Latest SEC Filings

OGI Stock Data